<SEC-DOCUMENT>0001213900-21-052090.txt : 20211008
<SEC-HEADER>0001213900-21-052090.hdr.sgml : 20211008
<ACCEPTANCE-DATETIME>20211008170230
ACCESSION NUMBER:		0001213900-21-052090
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20211008
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211008
DATE AS OF CHANGE:		20211008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		211315933

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea148616-8k_abvcbiophar.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ABVC="http://abvcpharma.com/20211008">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_ABVC_abvcpharma.com_20211008 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20211008_20211008 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20211008.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-10-08to2021-10-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-08</xbrli:startDate>
        <xbrli:endDate>2021-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20211008__20211008_zKGMssnA9mHe"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90F_edei--DocumentPeriodEndDate_c20211008__20211008_zVlBqUSUejsi"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 8, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20211008__20211008_zp2WzavMyFCd"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20211008__20211008_zWW1gRl0U12b"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityFileNumber_c20211008__20211008_zV36DonCMny1"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityFileNumber">333-91436</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20211008__20211008_zOcyY8KDZUG9"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(State or other jurisdiction<br />
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20211008__20211008_zd7GEVWBPW22"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20211008__20211008_zcg9j0ZnjWhi"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20211008__20211008_zDtCwPq8HtR4"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> </span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20211008__20211008_zyurFlt8SVgl"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b><span id="xdx_90E_edei--CityAreaCode_c20211008__20211008_zhjD2ZyAOiXi"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:CityAreaCode">(510)</ix:nonNumeric></span> <span id="xdx_90B_edei--LocalPhoneNumber_c20211008__20211008_zWovfHu1VkVa"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--WrittenCommunications_c20211008__20211008_zh1ZZo4eq3x2"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--SolicitingMaterial_c20211008__20211008_zhYSTPzkqN1i"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementTenderOffer_c20211008__20211008_zo9rKf8D8ek5"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20211008__20211008_zUejkVIo2I6e"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act: None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span id="xdx_909_edei--EntityEmergingGrowthCompany_c20211008__20211008_zZJgqT7OWl71"><ix:nonNumeric contextRef="From2021-10-08to2021-10-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 6, 2021 (the &#8220;<b>Completion Date</b>&#8221;),
ABVC BioPharma, Inc. (the &#8220;<b>Company</b>&#8221;), Lucidaim Co., Ltd., a Japanese corporation (&#34;<b>Lucidaim</b>,&#34; together
with the Company, the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#34;<b>Biolite&#8221;</b>)
entered into a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite is a private limited company (a Japanese <i>Kabushiki
Kaisha</i>) incorporated on December 18, 2018 and at the date of the Agreement has 10,000 ordinary shares authorized, with 3,049 ordinary
shares issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim
owned 1,501 ordinary shares and the Company owned the 1,548 ordinary shares. The Shareholders entered into the joint venture to formally
reduce to writing their desire to invest in and operate Biolite as a joint venture. The business of the joint venture shall be the research
and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements
carried on by Biolite and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment
to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals, which
have been received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement and the related share
transfer agreement, the Company shall transfer 54 of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer,
Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). Also pursuant to the Agreement,
there shall be 3 directors of Biolite, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company shall
appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi; the
current director of Biolite, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second Lucidaim
director. The Agreement further provides that the Company and Biolite shall assign the research collaboration and license agreement between
them to Biolite or prepare the same (the &#8220;<b>License Agreement</b>&#8221;). The aforementioned transactions occurred on the Completion
Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As per the Agreement, the Shareholders shall supervise
and manage the business and operations of Biolite. The directors shall not be entitled to any renumeration for their services as a director
and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all of its Ordinary
Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain corporate actions
that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;). If the Shareholders are unable to make a decision
on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days after which they must refer
the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute. If such dispute is not resolved within 10 days
thereafter, then either Shareholder can offer to buy all of the other Shareholder&#8217;s Ordinary Shares for cash at a specified price;
if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Shareholders maintains a pre-emptive
right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite
if Biolite issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under certain
conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s
Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement also requires Biolite to obtain
a bank facility in the amount of JPY 30,460,000 (approximately USD272,000), for its initial working capital purposes. Pursuant to the
Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be liable
for the bank facility in an amount up to JPY 14,925,400 (approximately USD134,000), which represents 49% of the maximum bank facility.
The Agreement further provides that Biolite shall issue annual dividends at the rate of at least 1.5% of Biolite&#8217;s profits, if it
has sufficient cash to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, the Company and Biolite
agree to use their best efforts to execute the License Agreement by the end of December 2021. The Company agreed that any negotiation
on behalf of Biolite regarding the terms of the License Agreement shall be handled by the directors appointed by Lucidaim. If the Company
and such Lucidaim directors do not reach agreement on the terms, Biolite may at its sole discretion determine not to execute the License
Agreement without any liability to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains non-solicitation and non-compete
clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited
to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite&#8217;s
activities, shall belong to Biolite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains standard indemnification
terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY 500,000 (approximately
USD4,500) and until the aggregate amount of all liabilities exceeds JPY 2,000,000 (approximately USD18,000) and then only to the extent
such liability exceed such limit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid $100,000 towards the setup of
the joint venture after the parties signed a letter of intent regarding the joint venture (the &#8220;<b>Letter of Intent</b>&#8221;)
and shall pay an additional $50,000 before the end of this calendar year; BioLite Japan&#8217;s other shareholder paid $150,000 after
the Letter of Intent was signed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement shall continue for 10 years, unless
earlier terminated and shall continue until terminated by: (i) either party by giving the other party at least 6 months written notice,
until the end of the 10 years, after which the parties can terminate at any time or (ii) or by written agreement of all Shareholders,
in which case it shall terminate automatically on the date upon which all Ordinary Shares are owned by one Shareholder. The Agreement
also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder, as set forth in the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This was a&#160;<i>related</i>&#160;<i>party</i>&#160;transaction
and was conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors providing approval for the Company to enter
into the Agreement, the Company&#8217;s audit committee approved the Company&#8217;s entry into the Agreement. The Board believes that
this joint venture will enhance the Company&#8217;s ability to provide therapeutic solutions to significant unmet medical needs and to
develop innovative botanical drugs to treat central nervous system (&#8220;CNS&#8221;) and oncology/ hematology diseases. The Company&#8217;s
Board of Directors believes that the joint venture has the potential to provide the Company with access to additional early-stage product
candidates that it would not otherwise have access to and to introduce the Company to early-stage opportunities, and therefore the Board
believes the joint venture is in the best interest of the Company and its shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of the Agreement is attached hereto as
Exhibit 10.1 and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Description&#160;of&#160;Exhibits</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">10.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea148616ex10-1_abvcbiopharma.htm"><span style="font-family: Times New Roman, Times, Serif">Joint Venture Agreement between the Company, Lucidaim Co., Ltd. and BioLite Japan K.K.</span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"><b>ABVC BIOPHARMA, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">October 8, 2021</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">/s/ Andy An</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Andy An</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">4</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5Fk2KgvbToiJWkSLib7BbCbbZskmrHslbGlvEZWFZZt6MECOxobWpkOGyzDM4Yd1U2iPkWCKjvWJwpNtdAuHmeDPOs7a+f39gSoHBwMzGSuog9NbOOCwSUHIi55NYgVwkUwXHvYi+ekq2NAVab3QF2hZwZGrYoNf8GhJO+kmW6ldfdUZ2hmyIG8tBfkMsVQwH6vSD+O4gy1IRjfqJxIapbb41rfNUw6rCOnS5Af1v9AEWOElH -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea148616ex10-1_abvcbiopharma.htm
<DESCRIPTION>JOINT VENTURE AGREEMENT BETWEEN THE COMPANY, LUCIDAIM CO., LTD. AND BIOLITE JAPAN K.K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Joint
Venture Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">dated</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">October 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ABVC Biopharma,
inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABVC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Lucidaim Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Lucidaim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">BioLite Japan K.K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Table of contents</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%; text-align: justify"><B>1.</B></TD>
    <TD STYLE="width: 90%; text-align: justify"><B>Interpretation</B></TD>
    <TD STYLE="width: 5%; text-align: center"><B>1</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>2.</B></TD>
    <TD STYLE="text-align: justify"><B>Conditions</B></TD>
    <TD STYLE="text-align: center"><B>5</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>3.</B></TD>
    <TD STYLE="text-align: justify"><B>Subscription for Shares</B></TD>
    <TD STYLE="text-align: center"><B>5</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>4.</B></TD>
    <TD STYLE="text-align: justify"><B>The Business</B></TD>
    <TD STYLE="text-align: center"><B>6</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>5.</B></TD>
    <TD STYLE="text-align: justify"><B>Directors and management</B></TD>
    <TD STYLE="text-align: center"><B>6</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>6.</B></TD>
    <TD STYLE="text-align: justify"><B>Financing</B></TD>
    <TD STYLE="text-align: center"><B>8</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>7.</B></TD>
    <TD STYLE="text-align: justify"><B>Shareholders&rsquo; consent</B></TD>
    <TD STYLE="text-align: center"><B>9</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>8.</B></TD>
    <TD STYLE="text-align: justify"><B>Continuing obligations</B></TD>
    <TD STYLE="text-align: center"><B>9</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>9.</B></TD>
    <TD STYLE="text-align: justify"><B>Distribution policy</B></TD>
    <TD STYLE="text-align: center"><B>10</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>10.</B></TD>
    <TD STYLE="text-align: justify"><B>Restrictive covenants</B></TD>
    <TD STYLE="text-align: center"><B>11</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>11.</B></TD>
    <TD STYLE="text-align: justify"><B>Intellectual Property</B></TD>
    <TD STYLE="text-align: center"><B>12</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>12.</B></TD>
    <TD STYLE="text-align: justify"><B>Transfer of Shares</B></TD>
    <TD STYLE="text-align: center"><B>12</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>13.</B></TD>
    <TD STYLE="text-align: justify"><B>Term and termination</B></TD>
    <TD STYLE="text-align: center"><B>15</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>14.</B></TD>
    <TD STYLE="text-align: justify"><B>Deadlock</B></TD>
    <TD STYLE="text-align: center"><B>17</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>15.</B></TD>
    <TD STYLE="text-align: justify"><B>Representation and Warranties</B></TD>
    <TD STYLE="text-align: center"><B>18</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>16.</B></TD>
    <TD STYLE="text-align: justify"><B>Confidentiality and announcements</B></TD>
    <TD STYLE="text-align: center"><B>19</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>17.</B></TD>
    <TD STYLE="text-align: justify"><B>Relationship with ABVC Group and Lucidaim Group</B></TD>
    <TD STYLE="text-align: center"><B>20</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>18.</B></TD>
    <TD STYLE="text-align: justify"><B>Tax matters</B></TD>
    <TD STYLE="text-align: center"><B>21</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>19.</B></TD>
    <TD STYLE="text-align: justify"><B>Conflict with articles</B></TD>
    <TD STYLE="text-align: center"><B>21</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>20.</B></TD>
    <TD STYLE="text-align: justify"><B>No partnership</B></TD>
    <TD STYLE="text-align: center"><B>21</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>21.</B></TD>
    <TD STYLE="text-align: justify"><B>Survival of Representations and Warranties; Indemnification</B></TD>
    <TD STYLE="text-align: center"><B>21</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>22.</B></TD>
    <TD STYLE="text-align: justify"><B>Counterparts</B></TD>
    <TD STYLE="text-align: center"><B>24</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>23.</B></TD>
    <TD STYLE="text-align: justify"><B>Further assurance</B></TD>
    <TD STYLE="text-align: center"><B>24</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>24.</B></TD>
    <TD STYLE="text-align: justify"><B>Waiver</B></TD>
    <TD STYLE="text-align: center"><B>24</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>25.</B></TD>
    <TD STYLE="text-align: justify"><B>Entire agreement</B></TD>
    <TD STYLE="text-align: center"><B>25</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>26.</B></TD>
    <TD STYLE="text-align: justify"><B>Notices</B></TD>
    <TD STYLE="text-align: center"><B>25</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>27.</B></TD>
    <TD STYLE="text-align: justify"><B>Costs</B></TD>
    <TD STYLE="text-align: center"><B>26</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>28.</B></TD>
    <TD STYLE="text-align: justify"><B>No Third-Party Beneficiaries</B></TD>
    <TD STYLE="text-align: center"><B>26</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>29.</B></TD>
    <TD STYLE="text-align: justify"><B>Amendments</B></TD>
    <TD STYLE="text-align: center"><B>26</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>30.</B></TD>
    <TD STYLE="text-align: justify"><B>Continuing effect</B></TD>
    <TD STYLE="text-align: center"><B>26</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>31.</B></TD>
    <TD STYLE="text-align: justify"><B>Illegality and Severability</B></TD>
    <TD STYLE="text-align: center"><B>26</B></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 5%"><B>32.</B></TD>
    <TD STYLE="text-align: justify; width: 90%"><B>Successors and Assigns</B></TD>
    <TD STYLE="text-align: center; width: 5%"><B>27</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>33.</B></TD>
    <TD STYLE="text-align: justify"><B>Governing law and Arbitration</B></TD>
    <TD STYLE="text-align: center"><B>27</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>34.</B></TD>
    <TD STYLE="text-align: justify"><B>Advice of Counsel</B></TD>
    <TD STYLE="text-align: center"><B>27</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>35.</B></TD>
    <TD STYLE="text-align: justify"><B>Captions</B></TD>
    <TD STYLE="text-align: center"><B>27</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><B>36.</B></TD>
    <TD STYLE="text-align: justify"><B>Governing language</B></TD>
    <TD STYLE="text-align: center"><B>27</B></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditions Precedent</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reserved Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part 1: Roulette Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part 2: Acceptance Notice</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share Transfer Provisions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Exhibit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form of Share Transfer Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Joint Venture Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>This Agreement</B> is dated
October 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>ABVC BioPharma, Inc.</B>,
a Nevada corporation with its principal place of business located at 44370 Old Warm Springs Blvd., Fremont, CA 94538, U.S.A. (&ldquo;<B>ABVC</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Lucidaim Co., Ltd.</B>, a
Japanese corporation with its principal place of business located at 4-26-37 Najima, Higashi-ku, Fukuoka-shi, Fukuoka 813-0043, Japan
(&ldquo;<B>Lucidaim</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>BioLite Japan K.K.</B>, a
Japanese corporation with its principal place of business located at 3-8-3 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan (&ldquo;<B>Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">ABVC, Lucidaim and Company are
referred to herein individually as a &ldquo;<B>Party</B>&rdquo; and, collectively, the &ldquo;<B>Parties</B>&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recitals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: -35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.3pt">A.</TD><TD STYLE="text-align: justify">WHEREAS, the Company is a private limited company (a Japanese <I>Kabushiki Kaisha</I>) incorporated on
18 December 2018 and at the date of this Agreement has an issued share capital of JPY thirty million four hundred ninety thousand (30,490,000)
with three thousand forty nine (3,049) ordinary shares. One thousand five hundred one (1,501) ordinary shares out of such three thousand
forty nine (3,049) ordinary shares have been issued nil paid and are held by Lucidaim and the remaining one thousand five hundred forty
eight (1,548) ordinary shares have been issued nil paid and are held by ABVC. Further details of the Company as at the time immediately
prior to the execution of this Agreement are set out in Schedule 1;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: -35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.3pt">B.</TD><TD STYLE="text-align: justify">WHEREAS, the Shareholders now wish to invest in and operate the Company as a joint venture for the purposes
and on the terms set out below; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: -35.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.3pt">C.</TD><TD STYLE="text-align: justify">WHEREAS, the Shareholders propose to conduct the business operations of the Company as set forth in, subject
to, and under the terms and conditions contained in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NOW, THEREFORE, in consideration
of the mutual agreements and undertakings contained herein, the Parties, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>AGREEMENT</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.</TD><TD STYLE="text-align: justify">Definitions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The following terms
used in this Agreement have the meanings ascribed to them below (unless otherwise expressly provided herein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>ABVC Director</B>&rdquo;
means a director appointed by ABVC in accordance with the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>ABVC Group</B>&rdquo;
means the group of companies comprising ABVC, any holding company from time to time of ABVC and any subsidiary of ABVC or of any such
holding company and &ldquo;<B>member of the ABVC Group</B>&rdquo; shall be construed accordingly. ABVC Group includes without limitation
BioFirst Corporation, a Taiwanese corporation with its principal place of business located at 3F, 248, Sec 1 Neihu Rd, Taipei, 11493,
Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>ABVC Indemnified
Parties</B>&rdquo; has the meaning set forth in Section&nbsp;21.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, any Person directly or indirectly Controlling, Controlled by, or under common Control with such other
Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Ancillary
Agreements</B>&rdquo; means License Agreement and any other agreement between the Parties or their respective Affiliates to be executed
in the agreed form, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Anti-Corruption
Laws</B>&rdquo; means any applicable foreign or domestic anti-bribery and/or anti-corruption laws and regulations, including the Penal
Code in Japan (Act No. 45 of 1907 as amended), the Unfair Competition Prevention Act in Japan (Act No. 47 of 1993 as amended), the UK
Bribery Act 2010, the US Foreign Corrupt Practices Act 1977 and any laws and regulations intended to implement the OECD Convention on
Combating Bribery of Foreign Public Officials in International Business Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Articles</B>&rdquo;
means the new articles of association of the Company as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Associated
Company</B>&rdquo; means, in relation to a Shareholder, any holding company from time to time and any subsidiary of the Shareholder or
of any such holding company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Associated
Person</B>&rdquo; means, in relation to a company, a person (including an employee, agent or subsidiary) who performs services for or
on behalf of that company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Applicable
Law</B>&rdquo; means any applicable statute, law, rule, regulation, ordinance, order, code, ruling, judgment, writ, injunction, decree,
or other official act of or by any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Business</B>&rdquo;
means research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing
of supplements carried on by the Group in Japan or such other business or businesses as may from time to time be agreed by an amendment
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Business
Day</B>&rdquo; means a day other than a Saturday, Sunday, or other day on which commercial banks in Japan are authorized or required by
law to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Business
Plan</B>&rdquo; means the Business Plan for the Company in the agreed form and thereafter as amended from time to time by the Shareholders
in accordance with the provisions of this Agreement setting out details of the Company&rsquo;s strategic planning for the then current
and five succeeding Financial Years in respect of customers (including market development and capacity growth), resourcing, capital expenditure
and financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Companies
Act</B>&rdquo; means the Companies Act of Japan (Act No. 86 of 2005 as amended).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Change
of Control</B>&rdquo; means with respect to a Party, a change of the Person that has Control, directly or indirectly, of that Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Completion</B>&rdquo;
has the meaning set forth in Section&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Completion
Date</B>&rdquo; means the first Business Day following fourteen (14) days after the satisfaction or waiver of the last Condition to be
satisfied or waived or such other date as the Shareholders may agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Conditions</B>&rdquo;
means the conditions precedent referred to in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Confidential
Information</B>&rdquo; means Know How, trade secrets and other information of a confidential nature (including all proprietary technical,
industrial and commercial information and techniques in whatever form (including computer disks or tapes) that information may be recorded
or stored).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Consumption
Tax</B>&rdquo; means Japanese consumption tax as defined in the Consumption Tax Act in Japan (Act No. 108 of 1988 as amended).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Control</B>,&rdquo;
&ldquo;<B>Controlling</B>,&rdquo; or &ldquo;<B>Controlled</B>&rdquo; means the ownership of more than 50% of the equity interests of a
Person, or the right, contractual or otherwise, to control the management and operations of a Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Director</B>&rdquo;
means a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Encumbrance</B>&rdquo;
means, with respect to any property, any mortgage, lien, pledge, charge, security interest, restriction, preemptive, preferential, or
similar purchase rights, hypothecation, and/or encumbrances of any kind, title defect, easement, or invalidity of leasehold interests
in respect of such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Excluded
Liabilities</B>&rdquo; means (i) any indebtedness of the Parties; (ii) any Damages related or attributable to any business of the Parties
other than the Business; and (iii) any Damages related or attributable to the businesses of the Parties conducted prior to the Completion
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Execution
Date</B>&rdquo; has the meaning set forth in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Financial
Year</B>&rdquo; means the financial year of the Company being December 1 to November 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Group</B>&rdquo;
means the group of companies comprising the Company and any subsidiary or subsidiary undertaking of the Company and &ldquo;<B>member of
the Group</B>&rdquo; or &ldquo;<B>Group Company</B>&rdquo; shall be construed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Governmental
Authority</B>&rdquo; means (i) any foreign or domestic, federal, territorial, state, or local governmental authority; (ii) quasi-governmental
authority, instrumentality, court, commission, or tribunal; (iii) any regulatory, administrative, or other agency; or (iv) any political
or other subdivision, department, or branch of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Indemnified
Party</B>&rdquo; means the Party and/or other Persons having the right to be indemnified with respect to Liabilities by the Indemnifying
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Indemnifying
Party</B>&rdquo; has the meaning set forth in Section&nbsp;21.4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Indemnity
Deductible</B>&rdquo; has the meaning set forth in Section&nbsp;21.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Individual
Indemnity Threshold</B>&rdquo; has the meaning set forth in Section&nbsp;21.3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Insolvency
Event</B>&rdquo; means, by reference to any member of the Group:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">a court making an order for the winding-up, bankruptcy, dissolution, liquidation, administration, reorganisation
or rehabilitation (excluding any solvent reorganisation otherwise permitted by the Finance Documents) of the relevant member of the Group,
or a liquidator or administrator or equivalent (but not a receiver, manager, or equivalent appointed by the holder of a Security) is appointed
to the relevant member of the Group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">the relevant member of the Group assigning its assets for the benefit of its creditors or entering into
any composition or arrangement with its creditors generally or any arrangement being ordered or declared whereby its affairs and/or its
assets are submitted to the control of, or are protected from, its creditors, including pursuant to any moratorium; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">any event analogous to any of the foregoing occurs in relation to the relevant member of the Group or
its assets in any jurisdiction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Intellectual
Property</B>&rdquo; means rights in and in relation to Confidential Information, trade marks, service marks, trade and business names,
logos and get up (including any and all goodwill associated with or attached to any of the same), domain names, patents, inventions (whether
or not patentable), registered designs, design rights, copyrights (including rights in software) and moral rights, database rights, semi-conductor
topography rights, utility models and all rights or forms of protection having an equivalent or similar nature or effect anywhere in the
world, whether enforceable, registered, unregistered or registrable (including, where applicable, all applications for registration) and
the right to sue for damages for past and current infringement (including passing off and unfair competition) in respect of any of the
same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Japanese
GAAP</B>&rdquo; means generally accepted accounting principles prescribed in Japan in effect from time to time</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Know How</B>&rdquo;
means all unpatented, secret, substantial and identified know how, expertise, technical or other information including all related ideas,
concepts, methods, inventions, discoveries, data, formulae, processes, methods, techniques and specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Loan Notes</B>&rdquo;
means loan agreements between the Company and a Shareholder to be executed in the agreed form pursuant to Section 6.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Liabilities</B>&rdquo;
means any and all claims, obligations, causes of action, payments, charges, judgments, assessments, liabilities, losses, damages, penalties,
fines, costs, and expenses, including any reasonable attorneys&rsquo; and experts&rsquo; fees, legal, or other expenses incurred in connection
therewith, including, without limitation, liabilities, costs, losses, and damages for personal injury, death, property damage, or environmental
damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>License
Agreement</B>&rdquo; means the research collaboration and license agreement between ABVC and the Company to be executed in the agreed
form, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Lucidaim
Director</B>&rdquo; means a director appointed by Lucidaim in accordance with the Articles and &ldquo;<B>Lucidaim Directors</B>&rdquo;
shall be construed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Lucidaim
Group</B>&rdquo; means the group of companies comprising Lucidaim, any holding company from time to time of Lucidaim and any subsidiary
of Lucidaim or of any such holding company and &ldquo;<B>member of the Lucidaim Group</B>&rdquo; shall be construed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Lucidaim
Indemnified Parties</B>&rdquo; has the meaning set forth in Section 21.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Party&rdquo;
or &ldquo;Parties</B>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Person</B>&rdquo;
means an individual, a corporation, a partnership, a limited liability company, an association, a trust, or any other entity or organization,
including a government or political subdivision or an agency or instrumentality thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Reserved
Matters</B>&rdquo; means those matters listed in Schedule 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Shareholder</B>&rdquo;
means Lucidaim or ABVC and/or any person to whom Shares are transferred or issued in accordance with this Agreement (or who is a successor
to Lucidaim or ABVC or such other person where a Termination Notice under Section 13.4 has not been served in connection with a merger
or consolidation) from time to time and &ldquo;<B>Shareholders</B>&rdquo; shall be construed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Shares</B>&rdquo;
means the ordinary shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Tax</B>&rdquo;
includes all taxes, duties, levies, imposts, withholdings, social security contributions, deductions or amounts in the nature of taxation,
whenever and by whatever authority imposed and whether of Japan or elsewhere, irrespective of the person against or to which any such
taxes, duties, levies, imposts, withholdings, social security contributions, deductions or amounts in the nature thereof are directly
or primarily chargeable, together with all interest, fines, penalties and surcharges imposed pursuant to any legislation relating to taxation
and which are incidental or relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Tax Authority</B>&rdquo;
means any person, body, authority or institution which seeks to impose, assess, enforce, administer or collect any Tax whether in Japan
or elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Third
Party</B>&rdquo; means any Person other than a Party to this Agreement or an Affiliate of a Party to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&ldquo;<B>Third-Party
Claim</B>&rdquo; has the meaning set forth in Section&nbsp;21.4(a).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.</TD><TD STYLE="text-align: justify">Conditions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.1</TD><TD STYLE="text-align: justify">Conditional Completion</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Completion is conditional
on those matters listed in Schedule 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.2</TD><TD STYLE="text-align: justify">Waiver of Conditions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Lucidaim may in
its absolute discretion waive either in whole or in part at any time by notice to ABVC any of the Conditions detailed in Schedule 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.3</TD><TD STYLE="text-align: justify">Shareholders&rsquo; commitments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each of the Shareholders
undertakes to use all reasonable endeavours to ensure that the Conditions are fulfilled as soon as reasonably practicable and in any event
by the end of August 2021.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.</TD><TD STYLE="text-align: justify">Transfer of Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.1</TD><TD STYLE="text-align: justify">Obligations of the Parties on Completion</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">On the Completion
Date :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">the Shareholders shall procure that a decision by Director of the Company is implemented for general meetings
of the Company shall be held on short notice at which special resolutions are passed to, approve transfer of the Shares referred to in
Section 3.1(b);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">subject to completion of the matters referred to in Section 3.1(a), the Shareholders shall execute share
transfer agreement in the form attached here to as Exhibit (&ldquo;<B>Share Transfer</B>&rdquo;) so that each Shareholder shall own the
following Shares, respectively, at the completion of the Share Transfer:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subscriber</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number and Class of Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucidaim</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,555 ordinary shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,494 ordinary shares</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">the Company shall update the register of members of the Company to reflect the Share Transfer pursuant
to Section 3.1(b);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">the Shareholders shall procure that a decision by Director of the Company is implemented for general meetings
of the Company shall be held on short notice at which special resolutions are passed to, approve appointment of directors of the Company
referred to in Section 3.1(e).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">subject to completion of the matters referred to in Section 3.1(d), the Shareholders shall procure that,
in addition to Toru Seo, who is the existing Lucidaim Director, the following person is appointed as directors of the Company with the
following designations:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Designation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michihito Onishi</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lucidaim Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Designation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC Director</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(f)</TD><TD STYLE="text-align: justify">the Parties who are also parties to License Agreement shall enter into the same or, if License Agreement
itself is yet to be ready, its term sheet or memorandum to provide main terms and conditions of it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.2</TD><TD STYLE="text-align: justify">Non-performance of obligations on Completion</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If any of the provisions
of Section 3.1 are not complied with in any respect by any of the Parties on the date upon which Completion is proposed to take place,
Lucidaim may in its absolute discretion (in addition and without prejudice to any other remedy available to it):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">defer Completion by a period of not more than twenty eight (28) days to such other date as it may specify
in such notice (and so that the provisions of this Section 3.2 shall apply to Completion as so deferred);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">waive all or any of the requirements (save for those which it alone is responsible) contained or referred
to in Section 3.1 at its discretion (and without prejudice to its rights under this Agreement) and proceed to Completion so far as practicable;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">refuse to perform its obligations under this Section and terminate this Agreement without liability on
its part.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.</TD><TD STYLE="text-align: justify">The Business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.1</TD><TD STYLE="text-align: justify">Nature of the Business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
shall procure that the Group shall carry on the Business (or such other business(es) in such other territor(y)(ies) as may from time to
time be agreed by an amendment to this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.2</TD><TD STYLE="text-align: justify">The Business Plan</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Business shall
be conducted in accordance with the Business Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.</TD><TD STYLE="text-align: justify">Directors and management</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.1</TD><TD STYLE="text-align: justify">Supervision by the Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
shall have responsibility for the overall direction, supervision and management of the Company and the Business including in respect of
those matters which are specifically provided in Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.2</TD><TD STYLE="text-align: justify">Number of Directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Unless otherwise
agreed in writing by the Shareholders, the number of Directors at all times during the term of this Agreement shall be three which shall
be made up of one ABVC Director and two Lucidaim Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.3</TD><TD STYLE="text-align: justify">Appointment and removal of Directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each Shareholder
may remove a Director appointed by it and appoint a new Director in his place by notice to the Company and the other Shareholder provided
that neither Shareholder shall appoint a Director without reasonable prior consultation with the other Shareholder with a view to reaching
agreement on the person to be appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.4</TD><TD STYLE="text-align: justify">Remuneration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Directors shall
not be entitled to any remuneration in their capacity as directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.5</TD><TD STYLE="text-align: justify">Resignation of Directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">At the time of the
completion of any sale, assignment, transfer or other disposition of all of the Shares held by a Shareholder, that Shareholder shall procure
the resignation of each Director appointed by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.6</TD><TD STYLE="text-align: justify">Indemnity</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Any Shareholder
removing a Director shall be responsible for and agrees to indemnify the other Shareholder and the Company on demand against all Liabilities
which the other Shareholder or the Company may suffer or incur arising out of, or in connection with, any claim by the Director for wrongful
or unfair dismissal or redundancy or other compensation arising out of the Director&rsquo;s removal or loss of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.7</TD><TD STYLE="text-align: justify">Directors&rsquo; meetings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Meetings of the
Directors shall be properly convened and held at such times as may be determined by the Shareholders and in any event at least one every
three months at the Company&rsquo;s principal place of business in Japan or such other place as the Directors may from time to time determine.
No Directors meeting shall be convened on less than five (5) Business Days&rsquo; notice unless at least one ABVC Director and one Lucidaim
Director approve a shorter notice period. Any notice of a Directors meeting shall include an agenda identifying in reasonable detail the
matters to be discussed at the meeting and shall be accompanied by copies of any relevant papers to be discussed at the meeting. Any action
to be taken at any Directors meeting may be taken without a meeting if all directors consent to such action in writing and the auditor
accept it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.8</TD><TD STYLE="text-align: justify">Quorum</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The quorum for transacting
business at any Directors&rsquo; meeting shall be at least one ABVC Director and at least one Lucidaim Director present when the relevant
business is transacted. Nothing in this Section shall be interpreted as prohibiting Directors&rsquo; meetings held by telephone or other
electronic communication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.9</TD><TD STYLE="text-align: justify">Voting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Directors shall
decide on matters by simple majority vote. Each Director shall have one vote.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.</TD><TD STYLE="text-align: justify">Financing</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.1</TD><TD STYLE="text-align: justify">Proceeds of subscription for Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The subscription
moneys shall be applied by the Company solely for the purposes specified in the Business Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.2</TD><TD STYLE="text-align: justify">Pre-emptive right</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">6.2.1</TD><TD STYLE="text-align: justify">If there is an issuance of new Shares (or any other type of security that is convertible into Shares)
pursuant to the terms and conditions of this Agreement and Applicable Laws, each of the Shareholders shall have the right (but not the
obligation) to subscribe for such newly issued Shares (or any other type of security that is convertible into Shares) such that subsequent
to the subscription, each Shareholder will maintain its shareholding percentage at the shareholding percentage (on an as converted and
fully diluted basis) of the Company that such Shareholder held immediately prior to the relevant issuance of new Shares (or any other
type of security that is convertible into Shares). To the extent one Shareholder does not elect to subscribe for such issuance of new
Shares (or any other type of security that is convertible into Shares), the other Shareholder shall have the right (but not the obligation)
to subscribe for such unsubscribed for Shares (or any other type of security that is convertible into such unsubscribed for Shares).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">6.2.2</TD><TD STYLE="text-align: justify">In the event that ABVC fails to go public on the New York Stock Exchange by the end of December 2021,
ABVC shall not have the pre-emptive right under Section 6.2.1 on and after January 1, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bank
facility</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0.15pt">The Company shall
arrange a facility for its initial working capital (the &ldquo;<B>Bank Facility</B>&rdquo;) with Mizuho Bank (or such other bank as the
Shareholders may select which offers more favourable terms) (the &ldquo;<B>Bank</B>&rdquo;). The amount of the Bank Facility shall be
JPY 30,460,000 or such other amount as the Bank will lend without requiring any recourse to either Shareholder. To the extent required
by the Bank, the Shareholders shall severally guarantee the Bank Facility. The proportions in which the Shareholders shall each be required
to guarantee the Company&rsquo;s obligations shall not exceed the proportion in which the Shareholders respectively hold Shares. The Bank
Facility shall be on the basis that the Bank will not acquire the right to participate in the share capital of the Company or otherwise
in the Business. To the extent required by the Bank, the Shareholders shall subordinate any Loan Notes to all sums owed to the Bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.4</TD><TD STYLE="text-align: justify">Further Finance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
acknowledge that the Company may require further finance to fund its projected cash requirements under the Business Plan and agree that
the Company may borrow additional sums from third parties on the most favourable terms available as to interest, repayment and security
compatible with its needs, but shall not allow any prospective lender the right to participate in the share capital of the Company or
otherwise in the Business as a condition or term of any loan or advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.5</TD><TD STYLE="text-align: justify">Guarantees</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Except to the extent
required pursuant to Section 6.3 or with the written consent of each Shareholder, neither Shareholder shall be obliged to provide guarantees
or security for any indebtedness of the Company. In the event that the Shareholders agree to give a joint and several guarantee or indemnity
to a third party in respect of any obligations of the Company, the following provisions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">subject to Section 6.5(b), as between the Shareholders, the aggregate liability of a Shareholder under
a joint and several guarantee or indemnity shall be in the same proportion as its holding of Shares at the time the guarantee or indemnity
is given;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">a Shareholder shall be responsible for the whole of any liability pursuant to the guarantee or indemnity
which is solely attributable to its own act or default or to that of any Director appointed by it; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">each Shareholder shall indemnify the other on demand for all amounts payable by the first-named Shareholder
pursuant to Sections 6.5(a) and 6.5(b).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms
of Guarantees etc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Any guarantee, indemnity
or other security provided pursuant to this Section 6 shall be provided by the Shareholders without cost to the Company and on such other
terms as the Shareholders may agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.7</TD><TD STYLE="text-align: justify">Subscription for Loan Notes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If the Shareholders
is unable to borrow funds from third parties on terms specified in Section 6.3, then the Company shall be funded by the issue of Loan
Notes on such terms as the Shareholders may agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.8</TD><TD STYLE="text-align: justify">Funding support by Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Except as otherwise
provided in this Agreement, neither Shareholder shall be obliged to provide any capital to the Company by way of subscription for further
Shares or by way of loans or subscription for Loan Notes unless they both agree on the amount and method of providing the finance. Unless
they agree otherwise, they shall contribute the same amount to the Company (whether by way of subscription for further Shares or by way
of loans or subscription for Loan Notes) at the same time and on the same terms.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.</TD><TD STYLE="text-align: justify">Shareholders&rsquo; consent</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.1</TD><TD STYLE="text-align: justify">The Shareholders shall take all steps to ensure, so far as they are legally able, that no decision relating
to the Reserved Matters is taken by the Company without the prior approval of each Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.2</TD><TD STYLE="text-align: justify">The Shareholders may give their approval of any of the Reserved Matters either in writing to the Company
or by voting in favour at a general meeting of the Company properly convened and held.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.</TD><TD STYLE="text-align: justify">Continuing obligations</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.1</TD><TD STYLE="text-align: justify">Accounting records</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Company shall
maintain accurate and complete accounting and other financial records in accordance with the Japanese GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.2</TD><TD STYLE="text-align: justify">Access to information</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">The Company shall provide each Shareholder and its authorised representatives with all information and
access, during normal business hours, as is necessary to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">keep it properly informed about the business and affairs of the Company and generally to protect its interests
as a Shareholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">satisfy itself that the provisions of Section 8.1 are being met; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">allow it to comply with any obligations to which it is subject under the laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.3</TD><TD STYLE="text-align: justify">Business Plan</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">The Shareholders shall prepare for the approval of the Shareholders a Business Plan for each Financial
Year which it shall submit to the Shareholders not less than thirty (30) Business Days before the end of the then current Financial Year
of the Company. Each Business Plan shall include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">a projected profit and loss account and balance sheet for the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">an estimate of the working capital requirements of the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">an operating budget for the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Subject to any amendments which they deem appropriate, the Shareholders shall approve the Business Plan
within the 30 Business Day period referred to in Section 8.3(a).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">The Shareholders shall review the Business Plan at quarterly intervals during the course of each Financial
Year and may propose changes to the Shareholders. The Shareholders shall respond to the Company within thirty (30) Business Days of receipt
of any proposal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">The Shareholders shall prepare for the approval of the Shareholders the first Business Plan which it shall
submit to the Shareholders by the end of December 2021. Subject to any amendments which they deem appropriate, the Shareholders shall
approve such first Business Plan by the end of March 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.4</TD><TD STYLE="text-align: justify">Approvals</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Company shall
use its best endeavours to obtain and maintain in full force and effect all approvals, consents and/or licences necessary for the conduct
of the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.5</TD><TD STYLE="text-align: justify">Shareholders&rsquo; Obligation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
shall procure that the Company complies with its obligations under this Section 8.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.</TD><TD STYLE="text-align: justify">Distribution policy</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.1</TD><TD STYLE="text-align: justify">The Shareholders shall take all steps to ensure that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">subject to the Company&rsquo;s cash requirements, the Company shall distribute by way of dividend in each
Financial Year at least 1.5 per cent. of the Company&rsquo;s profits available for distribution (within the meaning of Section 461 of
Companies Act) for that Financial Year; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">to the extent permitted by law, the Company shall pay dividends within thirty (30) days after the date
of the holding of the annual general meeting before which the audited accounts of the Company for the relevant Financial Year are laid,
save that the Company may pay interim dividends in accordance with the Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.2</TD><TD STYLE="text-align: justify">In deciding whether the Company has profits available for distribution in any Financial Year, the Company&rsquo;s
auditor shall be instructed to report (at the expense of the Company) the amount of the profits available for distribution by the Company
at the same time as they sign their report on the audited accounts of the Company for the relevant Financial Year. In giving such report,
the Company&rsquo;s auditors shall act as experts and not as arbitrators and their determination shall (in the absence of manifest error)
be final and binding on the Parties.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.</TD><TD STYLE="text-align: justify">Restrictive covenants</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.1</TD><TD STYLE="text-align: justify">Restriction of Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each Shareholder
covenants with the other Shareholder, the Company and each member of the Group that, except with the consent in writing of the other Shareholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">for so long as it, or any Associated Company of it, remains a member of the Company and (subject to Section
10.2) for a period of 2 years from the date on which it or any Associated Company of it ceases to be a member (the &ldquo;<B>Termination
Date</B>&rdquo;), it will not within any country in which any member of the Group carries on business, either on its own account or in
conjunction with or on behalf of any other person, carry on or be engaged, concerned or interested, directly or indirectly, whether as
shareholder, director, partner, agent or otherwise, in carrying on any business which competes with the business of any member of the
Group (other than as a holder of shares in a company carrying on such a business where the shareholding is for investment purposes only
and does not confer a degree of control amounting to or exceeding material influence over the business in question);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">for so long as it, or any Associated Company of it, remains a member of the Company and (subject to Section
10.2) for a period of 2 years from the Termination Date, it will not, either on its own account or in conjunction with or on behalf of
any other person, canvass, solicit or approach or cause to be canvassed, solicited or approached any person who is a client or customer,
prospective client or customer, representative or agent of any member of the Group or in the habit of dealing with any member of the Group
for the purpose of offering to that person goods or services which are of the same type as or similar to any goods or services supplied
by any member of the Group or enter into any contract for sale and purchase with or accept business from any such person in relation to
any such goods or services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">for so long as it, or any Associated Company of it, remains a member of the Company and for a period of
2 years from the Termination Date, it will not, either on its own account or in conjunction with or on behalf of any other person, interfere
or seek to interfere with the continuance of supplies to any member of the Group from any person who is a supplier of goods or services
to any member of the Group if such interference causes or would be likely to cause that supplier to cease supplying or materially to reduce
or alter the terms of its supply of such goods or services to any member of the Group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">for so long as it, or any Associated Company of it, remains a member of the Company and for a period of
2 years from the Termination Date, it will not either on its own account or in conjunction with or on behalf of any other person, solicit
or entice away or attempt to solicit or entice away from any member of the Group ,offer employment to or employ, or offer to conclude
any contract of services with, any person who is employed by or seconded to in a managerial, supervisory, technical or sales capacity,
or engaged as a consultant to, any member of the Group and who remains so employed, seconded or engaged immediately prior to the relevant
breach of this Section 10.1(d) (whether or not such person would commit a breach of contract by reason of leaving such employment, secondment
or engagement); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">it will not at any time hereafter in relation to any trade, business or company use a trade name, trade
or service mark, design or logo including the word &ldquo;BioLite Japan&rdquo; or &ldquo;BLJ&rdquo; or any word confusingly similar thereto
in such a way as to be capable of or likely to be confused with any trade name, trade or service mark, design or logo of any member of
the Group (whether registered or not).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.2</TD><TD STYLE="text-align: justify">Where a Shareholder, or any Associated Company of it, ceases to be a member of the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">for the purposes of Section 10.1(a), the business of any member of the Group shall be deemed to be that
carried on at the Termination Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">for the purposes of Section 10.1(b), the goods or services supplied by any member of the Group shall be
deemed to be those supplied as at the Termination Date or at any time within the year prior to the Termination Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.3</TD><TD STYLE="text-align: justify">Severance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each of the restrictions
contained in Sections 10.1(a) to 10.1(e) is separate and severable and in the event of any such restriction being determined to be unenforceable
in whole or in part for any reason, that unenforceability shall not affect the enforceability of the remaining restrictions or (in the
case of restrictions unenforceable in part) the remainder of that restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.4</TD><TD STYLE="text-align: justify">Modification of restrictions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">While the restrictions
contained in this Section 10 are considered by the Shareholders to be reasonable in all the circumstances, it is recognised that restrictions
of the nature in question may fail for technical reasons and accordingly it is hereby agreed and declared that if any of such restrictions
shall be adjudged to be void as going beyond what is reasonable in all the circumstances for the protection of the interests of the Group
but would be valid if part of the wording thereof were deleted or the periods thereof reduced or the range of activities or area dealt
with thereby reduced in scope, the said restriction shall apply with such modifications as may be necessary to make it valid and effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.5</TD><TD STYLE="text-align: justify">Restrictions on each Shareholder&rsquo;s group</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each Shareholder
shall procure that each of its Associated Companies shall be bound by and observe the provisions of this Section 10 as if they were parties
covenanting with the other Shareholder in the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.6</TD><TD STYLE="text-align: justify">Exception[s] from restrictions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The restrictions
contained in Section 10.1 shall not preclude any member of the ABVC Group from being interested in the business in any other areas than
the ophthalmologic field or the central neurological field and/or any member of the Lucidaim Group from being interested in the business
in any other areas than the ophthalmologic field or the central neurological field.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">11.</TD><TD STYLE="text-align: justify">Intellectual Property</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Any rights to Intellectual
Property which arise in the course of the Group&rsquo;s activities shall belong to the Company or, as the case may be, the relevant member
of the Group.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.</TD><TD STYLE="text-align: justify">Transfer of Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.1</TD><TD STYLE="text-align: justify">General prohibition</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Unless permitted
by this Section 12 or Section 3.1(b) or with the prior written consent of the other Shareholder, neither Shareholder shall do, or agree
to do, any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">sell, transfer or otherwise dispose of, any of its Shares or any interest in any of its Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Encumber any of its Shares or any interest in any of its Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">enter into any agreement or arrangement in respect of the votes or other rights attached to any of its
Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">enter into any agreement or arrangement to do any of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.2</TD><TD STYLE="text-align: justify">Initial period</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Except for transfers
to Associated Companies pursuant to Section 12.2, neither Shareholder shall transfer any Shares during a period of three years from
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.3</TD><TD STYLE="text-align: justify">Transfers to third parties</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Subject to Sections
12.2 and 12.3, either Shareholder (the &ldquo;<B>Selling Shareholder</B>&rdquo;) may transfer its Shares to a third party only if it
receives an offer (the &ldquo;<B>Offer</B>&rdquo;) which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">is a bona fide offer in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">is from a third party which has its own financial resources to meet its obligations under the Offer or
has a legally binding commitment from a lender for that finance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">is irrevocable during the period of the Offer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">is for cash consideration only and is for all the Shares of the Selling Shareholder and all the Shares
of the other Shareholder if it also elects to accept the Offer; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">contains all material terms and conditions (including the price and the intended completion date of the
Offer);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">and in circumstances
in which the Selling Shareholder complies with the remaining provisions of this Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.4</TD><TD STYLE="text-align: justify">Notice of Offers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If a Selling Shareholder
receives an Offer which it wishes to accept, it must immediately give written notice, including details of the proposed purchaser and
the purchase price for the Shares, (the &ldquo;<B>Transfer Notice</B>&rdquo;) to the other Shareholder (the &ldquo;<B>Remaining Shareholder</B>&rdquo;)
offering to sell those Shares which are the subject of the Offer to the Remaining Shareholder at the same cash price as set out in the
Offer and on terms which are no less favourable than those contained in the Offer. The Transfer Notice must also state:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">the period within which the offer to sell the Shares to the Remaining Shareholder shall remain open for
acceptance. This period must be at least thirty (30) Business Days from the date of service of the Transfer Notice (the &ldquo;<B>Acceptance
Period</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">full details of all other terms and conditions of the Offer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.5</TD><TD STYLE="text-align: justify">Options of Remaining Shareholder</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Once the Remaining
Shareholder has received a Transfer Notice it may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">send a written notice to the Selling Shareholder within the Acceptance Period accepting the offer set
out in the Transfer Notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">send a written notice to the Selling Shareholder within the Acceptance Period declining the offer set
out in the Transfer Notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">send a written notice to the Selling Shareholder (a &ldquo;<B>Sale Notice</B>&rdquo;) within the Acceptance
Period offering to sell all of its Shares to the third party on the same terms and conditions as those contained in the Offer; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">not reply to the Transfer Notice within the Acceptance Period or reply in a manner other than as specified
in Sections 12.5(a) to (c). In those cases, the Remaining Shareholder shall be deemed not to have accepted the offer set out in the Transfer
Notice and not to have issued a Sale Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.6</TD><TD STYLE="text-align: justify">Consequences of Transfer Notice</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">If the offer set out in the Transfer Notice is accepted, the Selling Shareholder must sell its Shares
to the Remaining Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">If the offer set out in the Transfer Notice is not accepted, or deemed not to be accepted, and a Sale
Notice is not issued, or deemed not to be issued, the Selling Shareholder may accept the Offer and sell its Shares on the terms and conditions
of the Offer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">If a Sale Notice is issued, the Selling Shareholder and the Remaining Shareholder must sell their Shares
on the terms and conditions of the Offer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.7</TD><TD STYLE="text-align: justify">Completion of transfer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The sale of Shares
pursuant to this Section 12 shall be made on the following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">completion of the transfer of the Shares shall take place seven (7) Business Days after the date of expiry
of the Acceptance Period (the &ldquo;<B>Transfer Date</B>&rdquo;) and at such reasonable time and place as the Shareholders agree or,
failing which, at noon at the registered office of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">the Selling Shareholder and, if relevant, the Remaining Shareholder must deliver to the purchaser in respect
of the Shares which it is selling on or before the Transfer Date:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">duly executed share transfer forms; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">a power of attorney in such form and in favour of such person as the purchaser may nominate to enable
the purchaser to exercise all rights of ownership in respect of the Shares to be sold including voting rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">the purchaser must pay the total consideration due for the Shares to the Selling Shareholder and, if relevant,
the Remaining Shareholder by same day transfer of funds to the bank account(s) notified to it for the purpose on the Transfer Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">if relevant, completion of the sale of the Shares of the Selling Shareholder and the Remaining Shareholder
must take place simultaneously; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">in accordance with the provisions of Schedule 5.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.8</TD><TD STYLE="text-align: justify">Failure to complete sale</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">If the Selling Shareholder and/or, if relevant, the Remaining Shareholder fail(s) or refuse(s) to comply
with its/their obligations in this Section 12, the Company may authorise a person to execute and deliver the necessary transfer on its/their
behalf. The Company may receive the purchase money in trust for the Selling Shareholder and/or, if relevant, the Remaining Shareholder
and cause the purchaser to be registered as the holder of the Shares being sold. The receipt of the Company for the purchase money shall
be a good discharge to the purchaser (who shall not be bound to see to the application of those moneys). After the purchaser has been
registered as holder of the Shares being sold in purported exercise of these powers, the validity of the proceedings shall not be questioned
by any person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">If a Shareholder fails or refuses to transfer any Shares in accordance with this Section&nbsp;12, the
other Shareholder may serve a default notice. At the end of the period of five (5) Business Days from the date of service of such a default
notice (unless the non-compliance has previously been remedied to the reasonable satisfaction of the other Shareholder), the defaulting
Shareholder shall not be entitled to exercise any of its/their powers or rights in relation to management of, and participation in the
profits of, the Company under this Agreement, the Articles or otherwise. The directors appointed by the defaulting Shareholder (or its
predecessor(s) in title) shall not:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">be entitled to vote at any directors meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">be required to attend any meeting of directors in order to constitute a quorum; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">be entitled to receive or request any information from the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.9</TD><TD STYLE="text-align: justify">General</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
shall keep the Company informed, at all times, of the issue and contents of any notice(s) served pursuant to this Section 12 and any election
or acceptance relating to those notices.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.</TD><TD STYLE="text-align: justify">Term and termination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.1</TD><TD STYLE="text-align: justify">Termination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Subject to Section
3.2, this Agreement can be terminated only in accordance with the following provisions of this Section13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.2</TD><TD STYLE="text-align: justify">Initial term and termination by notice thereafter</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement shall
(unless terminated at an earlier date pursuant to the terms of this Agreement) continue in force for an initial term (the &ldquo;<B>Initial
Term</B>&rdquo;) of ten years and shall continue in force after the Initial Term until terminated by either Shareholder giving to the
other Parties not less than six month notice of termination expiring at the end of the Initial Term or at any time after the Initial Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.3</TD><TD STYLE="text-align: justify">Termination by consent</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement may
be terminated at any time by the written agreement of the Shareholders and shall terminate automatically without notice on the date upon
which all of the Shares are owned by one Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.4</TD><TD STYLE="text-align: justify">Termination for default</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Either Shareholder
(the &ldquo;<B>Non-Defaulting Shareholder</B>&rdquo;) may terminate this Agreement by notice (&ldquo;<B>Termination Notice</B>&rdquo;)
to the other Shareholder (the &ldquo;<B>Defaulting Shareholder</B>&rdquo;) or to any successor to the Defaulting Shareholder in any case
within Section 13.4(h) if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">the Defaulting Shareholder commits a material breach or persistent breaches of its obligations under this
Agreement (whether such breach or breaches amount to a repudiatory breach or breaches or not) and, if the breaches are capable of remedy,
fails to remedy the breaches within twenty (20) Business Days of being specifically required in writing so to do by the Non-Defaulting
Shareholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">the Company terminates in accordance with its terms an Ancillary Agreement to which the Defaulting Shareholder
or an Associated Company of it is a party before expiration of the contractual term;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">the Company as non-Defaulting Shareholder determines not to execute the License Agreement in accordance
with Section 17.1.2;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">the Defaulting Shareholder sells or otherwise disposes of all or substantially all of its undertaking
or assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">the Defaulting Shareholder makes an assignment for the benefit of creditors generally or fails to pay
its debts generally as they become due or any material financial indebtedness of the Defaulting Shareholder becomes payable or capable
of being declared payable before its stated maturity date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(f)</TD><TD STYLE="text-align: justify">an Insolvency Event occurs in relation to the Defaulting Shareholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(g)</TD><TD STYLE="text-align: justify">there is a Change of Control of the Defaulting Shareholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(h)</TD><TD STYLE="text-align: justify">there is a merger or consolidation of the Defaulting Shareholder with any other person such that one of
the entities involved ceases to exist.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Defaulting Shareholder
shall forthwith give notice to the Non-Defaulting Shareholder of the occurrence of any of the events in Sections 13.4(a) to (h) and the
Non-Defaulting Shareholder may serve a Termination Notice no later than thirty (30) Business Days from the date of that notification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.5</TD><TD STYLE="text-align: justify">Transfer Notice</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Within five (5)
Business Days of receipt of a Termination Notice, the Defaulting Shareholder shall make an offer to the Non-Defaulting Shareholder by
notice (the &ldquo;<B>Transfer Notice</B>&rdquo;) stating a single price at which it would be prepared either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">to purchase the Shares of the Non-Defaulting Shareholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">to sell to the Non-Defaulting Shareholder the Shares of the Defaulting Shareholder</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">(in either case
these Shares are referred to as the &ldquo;<B>Sale Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.6</TD><TD STYLE="text-align: justify">Acceptance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Within five (5)
Business Days of receipt of the Transfer Notice, the Non-Defaulting Shareholder shall notify the Defaulting Shareholder whether it wishes
to purchase or sell the Sale Shares in accordance with the terms of the Transfer Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.7</TD><TD STYLE="text-align: justify">Dispute as to price</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If the Defaulting
Shareholder fails to serve a Transfer Notice in accordance with Section 13.5 or the Non-Defaulting Shareholder does not agree with the
price for the Sale Shares proposed by the Defaulting Shareholder, the Non-Defaulting Shareholder may by notice to the Defaulting Shareholder
require a price for the Sale Shares to be established by an independent chartered accountant (the &ldquo;<B>Valuer</B>&rdquo;) (acting
as an expert and not as an arbitrator). The Valuer shall be agreed upon by the Shareholders or, in default of agreement within five (5)
Business Days of receipt of the Non-Defaulting Shareholder&rsquo;s notice pursuant to this Section, appointed by the President for the
time being of the Institute of Chartered Accountants in England and Wales (or any person for the time being performing the functions of
that official) on the application of the Non-Defaulting Shareholder. The Valuer shall determine the fair price of the Shares being sold
on a going concern basis between a willing seller and a willing purchaser and on the basis that each Share, whatever its class, has the
same value corresponding to its proportion of the value of all the Shares taken as a whole and that no additional or reduced value is
attached to any holding of Shares by virtue only of that holding comprising or after purchase conferring or giving rise to a majority
or minority of the total issued share capital of the Company. Any costs of the Valuer shall be borne by the Defaulting Shareholder. Following
the determination of the price by the Valuer the Non-Defaulting Shareholder may by notice to the Defaulting Shareholder require the Defaulting
Shareholder either to purchase the Sale Shares or to sell to the Non-Defaulting Shareholder the Sale Shares at the price so established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.8</TD><TD STYLE="text-align: justify">Transfer of Sale Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Within two (2) Business
Days of the Non-Defaulting Shareholder notifying the Defaulting Shareholder whether it wishes to purchase or sell pursuant to Section
13.6 or Section 13.7, the appropriate Shareholder shall execute the necessary instrument(s) of transfer of the Sale Shares in favour of
the other Shareholder against payment in full of the price for the Sale Shares and the Shareholders shall procure that the Company will
enter the purchaser&rsquo;s name in the register of members of the Company as the holder of the Sale Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.9</TD><TD STYLE="text-align: justify">Business pending registration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Following service
of a Termination Notice until such time as the completion of the transfer of the Sale Shares pursuant to Section 13.8 (including, if appropriate,
the period of valuation or any period during which any matter relating to this Section is the subject of proceedings), each Shareholder
shall do all things in its power to continue to operate the Company in the ordinary course of its business as it existed at the time at
which the Termination Notice was served.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.10</TD><TD STYLE="text-align: justify">Mechanics of transfers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The provisions of
Schedule 5 shall apply to all transfers of Shares pursuant to this Section 13.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.</TD><TD STYLE="text-align: justify">Deadlock</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.1</TD><TD STYLE="text-align: justify">If the Shareholders are unable to arrive at a decision on any matter listed in Schedule 3, which is material
to the business of the Company, by reason of disagreement between themselves, then a deadlock shall be deemed to have occurred in relation
to the matter. Whenever a deadlock is deemed to have occurred, each Shareholder may, within twenty eight (28) days of the event that has
given rise to the deadlock, give notice to the other Shareholder that in its opinion there is a deadlock (&ldquo;<B>Deadlock Notice</B>&rdquo;)
and identifying the matter over which the Shareholders are deadlocked.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.2</TD><TD STYLE="text-align: justify">The Shareholders undertake that within a period of five (5) Business Days following service of the Deadlock
Notice they shall forthwith refer the matter which has given rise to the deadlock to the Chairman of each of the Shareholders and shall
each use all reasonable endeavours in good faith to resolve the dispute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.3</TD><TD STYLE="text-align: justify">If the deadlock has not been resolved within ten (10) Business Days from the date of referral to the Chairmen
under Section 14.2 (the &ldquo;<B>Referral Period</B>&rdquo;), then either Shareholder (in this Section 14 the &ldquo;<B>First Shareholder</B>&rdquo;)
may by notice in the form set out in Part 1 of Schedule 4 (the &ldquo;<B>Roulette Notice</B>&rdquo;) given at any time within ten (10)
Business Days of the expiry of the Referral Period offer to buy all of the other Shareholder&rsquo;s (the &ldquo;<B>Second Shareholder</B>&rdquo;)
Shares for cash at a price per Share specified in the Roulette Notice (the &ldquo;<B>Specified Price</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.4</TD><TD STYLE="text-align: justify">The Roulette Notice shall be deemed to constitute:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">an offer by the First Shareholder to purchase all (but not some only) of the Second Shareholder&rsquo;s
Shares at the Specified Price; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">an alternative offer by the First Shareholder to sell to the Second Shareholder all (but not some only)
of the First Shareholder&rsquo;s Shares at the Specified Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.5</TD><TD STYLE="text-align: justify">Within ten (10) Business Days of service of the Roulette Notice, the Second Shareholder may accept either
of the offers referred to in Section 14.4 by notice in the form set out in Part 2 of Schedule 4 (the &ldquo;<B>Acceptance Notice</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.6</TD><TD STYLE="text-align: justify">Service of the Acceptance Notice shall constitute an acceptance of the offer specified therein and:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">in the case of the offer contained in Section 14.4(a), the First Shareholder shall be bound to purchase,
and the Second Shareholder shall be bound to sell the Second Shareholder&rsquo;s Shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">in the case of the offer contained in Section 14.4(b), the First Shareholder shall be bound to sell, and
the Second Shareholder shall be bound to purchase, the First Shareholder&rsquo;s Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">in accordance with
the provisions of Section 14.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.7</TD><TD STYLE="text-align: justify">If no valid Acceptance Notice is served (or it is served incorrectly completed) by the Second Shareholder
under Section 14.5, then the First Shareholder shall be bound to purchase, and the Second Shareholder shall be bound to sell, the Second
Shareholder&rsquo;s Shares in accordance with the provisions of Section 14.8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.8</TD><TD STYLE="text-align: justify">Completion of the sale and purchase contemplated by this Section 14 shall be at the date, time and place
specified in the Roulette Notice. At that completion, the transferring Shareholder shall deliver or cause to be delivered to the purchasing
Shareholder (or as it may direct) a duly executed transfer or transfers in respect of the transferring Shareholder&rsquo;s Shares in favour
of the purchasing Shareholder (or as it may direct) and accompanied by the relative share certificates or other documents of title, together
with any power or authority under which such transfer or transfers have been executed, against which the purchasing Shareholder shall
pay by wire transfer to the bank account of the transferring Shareholder as notified in the Roulette Notice an amount equal to the Specified
Price multiplied by the relevant number of Shares being sold. The transferring Shareholder shall do all such other things and execute
all such other documents as the purchasing Shareholder may reasonably require to give effect to the sale and purchase of the relevant
Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.9</TD><TD STYLE="text-align: justify">No Roulette Notice or Acceptance Notice may be withdrawn except with the written consent of the Shareholder
to which it was given and save as aforesaid shall constitute a binding obligation on the Shareholders to sell and purchase the relevant
Shares in the manner contemplated by this Section 14.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">14.10</TD><TD STYLE="text-align: justify">The provisions of Schedule 5 shall apply to all transfers of Shares pursuant to this Section 14.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">15.</TD><TD STYLE="text-align: justify">Representations and Warranties</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each of the Shareholders
represents and warrants to the other that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">it has the full power and authority to enter into and to perform its obligations under the Transaction
Documents which, when executed, will constitute valid and binding obligations on it in accordance with its terms; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">the entry into and delivery of, and the performance by it of, the Transaction Documents will not result
in any breach of any provision of its articles of association or result in any claim by a third party against the other Shareholder or
the Company.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">16.</TD><TD STYLE="text-align: justify">Confidentiality and announcements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">16.1</TD><TD STYLE="text-align: justify">Confidentiality</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">This Section applies to all Confidential Information disclosed (whether in writing, verbally or by any
other means and whether directly or indirectly) by one Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) to any other Party (the &ldquo;<B>Receiving
Party</B>&rdquo;) whether before or after the date of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">During the term of this Agreement and after termination or expiration of this Agreement for any reason
whatsoever, the Receiving Party shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">keep the Confidential Information confidential;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">not disclose the Confidential Information to any other person other than with the prior written consent
of the Disclosing Party or in accordance with Sections 16.1(c) and 16.1(d); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">not use the Confidential Information for any purpose other than the performance of its obligations under
this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">During the term of this Agreement, the Receiving Party may disclose the Confidential Information to any
of its employees or advisers or those of members of the Group (the &ldquo;<B>Recipient</B>&rdquo;) to the extent that it is necessary
for the purposes of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(d)</TD><TD STYLE="text-align: justify">The Receiving Party shall procure that each Recipient is made aware of and complies with all the Receiving
Party&rsquo;s obligations of confidentiality under this Agreement as if the Recipient was a party to this Agreement. The Receiving Party
shall remain responsible for any breach of this Section 16 by the Recipient.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(e)</TD><TD STYLE="text-align: justify">The obligations contained in Sections 16.1(b) to 16.1(d) shall not apply to any Confidential Information
which:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">is at the date of this Agreement, or at any time after the date of this Agreement, comes into the public
domain other than through breach of this Agreement by the Receiving Party or any Recipient;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">can be shown by the Receiving Party to the reasonable satisfaction of the Disclosing Party to have been
known to the Receiving Party prior to it being disclosed by the Disclosing Party to the Receiving Party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">subsequently comes lawfully into the possession of the Receiving Party from a third party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iv)</TD><TD STYLE="text-align: justify">is required to be disclosed by law or any court of competent jurisdiction, any governmental, official
or regulatory authority or any binding judgment, order or requirement of any other competent authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(f)</TD><TD STYLE="text-align: justify">Without prejudice to any other rights or remedies which a Party may have, the Parties acknowledge and
agree that damages would not be an adequate remedy for any breach of this Section 16 and the remedies of injunction, specific performance
and other equitable relief are appropriate for any threatened or actual breach of any such provision and no proof of special damages shall
be necessary for the enforcement of the rights under this Section 16.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">16.2</TD><TD STYLE="text-align: justify">Announcements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">Subject to the provisions of Section 16.2(b), no disclosure or announcement relating to the existence
or subject matter of this Agreement shall be made or issued by or on behalf of any Party or any member of the group of companies of which
that Party is a member without the prior written approval of the other Parties (which approval may be subject to reasonable conditions
but shall otherwise not be unreasonably withheld or delayed) provided that these restrictions shall not apply to any disclosure or announcement
if required by any law, applicable securities exchange, supervisory, regulatory or governmental body.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Nothing in this Agreement will prohibit the Parties from making or sending after Completion any announcement
to a customer, client or supplier of the Company informing it of the establishment of the Business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">The Party making the communication shall use its reasonable endeavours to consult with the other Parties
in advance as to the form, content and timing of the communication.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">17.</TD><TD STYLE="text-align: justify">Relationship with ABVC Group and Lucidaim Group</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">17.1</TD><TD STYLE="text-align: justify">Ancillary Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">18.1.1</TD><TD STYLE="text-align: justify">Each Shareholder shall take all steps to perform, and shall procure that each member of the Group performs,
its obligations under the Ancillary Agreements to which it is a party. In the event that any dispute or difference arises between the
relevant member of the Group and either of the Shareholders or any of their Associated Companies in relation to the Ancillary Agreements
or any of them, the Shareholders agree that the conduct of any dispute or difference on behalf of the relevant member of the Group shall
be passed to the directors appointed by the Shareholder who is not itself party to the relevant Ancillary Agreement who shall have full
authority on behalf of the relevant member of the Group to negotiate, litigate and settle that dispute or difference, and each Shareholder
shall take all steps to give effect to this Section 17.1.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">18.1.2</TD><TD STYLE="text-align: justify">ABVC and the Company shall use its reasonable endeavours to execute the License Agreement by the end of
December 2021. ABVC agrees that the conduct of any negotiation on behalf of the Company for the terms of License Agreement shall be passed
to Lucidaim Directors who shall have full authority on behalf of the Company to negotiate the terms. In the event that ABVC and Lucidaim
Directors representing the Company do not reach agreement on the terms, the Company may at its sole discretion determine not to execute
the License Agreement without any liability to ABVC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">17.2</TD><TD STYLE="text-align: justify">Enforcement of Company&rsquo;s Rights</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Any right of action
which the Company may have in respect of breach of this Agreement or of any other obligation owed to the Company shall be prosecuted by
the Directors appointed by the Shareholder which is not, or whose Associated Company is not, responsible for the breach. Those Directors
shall have full authority on behalf of the Company to negotiate, litigate and settle any claim arising out of the breach or exercise any
right of termination arising out of the breach and the Shareholders shall take all steps within their power to give effect to the provisions
of this Section 17.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">17.3</TD><TD STYLE="text-align: justify">Anti-Corruption</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">Each Shareholder undertakes that it will, and will procure that its Associated Companies and each member
of the Group will:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">comply with the Anti-Corruption Laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">not engage in any activity, practice or conduct that may constitute a breach of the Anti-Corruption Laws;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">maintain any procedures under the Anti-Corruption Laws to prevent any Associated Person from undertaking
any conduct that may give rise to a breach of the Anti-Corruption Laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Each Shareholder undertakes that it will from time to time, at the reasonable request of the other Shareholder,
confirm in writing that it has complied with its undertakings under Section 17.3(a) and will provide any information reasonably requested
by the other Party in support of such compliance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">Each Shareholder agrees that it will indemnify the other Shareholder and its Associated Companies for
any Liabilities incurred as a result of its breach of Section 17.3(a).</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">18.</TD><TD STYLE="text-align: justify">Tax matters</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">In the event that
the Company shall, at any time, have available to it trading losses or other amounts eligible for relief from corporation tax, the Shareholders
shall procure that relief in respect of such amounts shall not be surrendered to either of the Shareholders without the prior written
consent of the other Shareholder and in the event that such relief is so surrendered to a Shareholder, the Shareholder receiving the relief
shall be responsible for any taxes incurred in connection with the surrender.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">19.</TD><TD STYLE="text-align: justify">Conflict with articles</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If there is any
conflict between the provisions of this Agreement and the provisions of the Articles, the Shareholders agree that, as between themselves
and for so long as this Agreement remains in force but not so as to amend the Articles, the provisions of this Agreement shall prevail
and the Shareholders shall exercise all voting and other rights and powers available to them to give effect to the provisions of this
Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">20.</TD><TD STYLE="text-align: justify">No partnership</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Nothing in this
Agreement (or any of the arrangements contemplated by it) is or shall be deemed to constitute a partnership between the Parties nor, except
as may be expressly set out in it, constitute any Party the agent of the others for any purpose.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">21.</TD><TD STYLE="text-align: justify">Survival of Representations and Warranties; Indemnification</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">21.1</TD><TD STYLE="text-align: justify">Survival of Representations and Warranties</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Notwithstanding
any investigation made by a Party or its authorized representatives with respect to the representations or warranties of the other Parties,
all representations and warranties of the Parties contained in this Agreement shall survive the Closing for a period of twenty-four (24)
months from and after the Completion Date. No claim for indemnification with respect to a breach of or inaccuracy in any representation
or warranty contained in this Agreement may be asserted after the expiration of the aforementioned twenty-four month period. Representations,
warranties, covenants, and agreements shall be of no further force or effect after the date of their expiration; <I>provided that</I>
there shall be no termination of any bona fide claim asserted pursuant to this Agreement with respect to such a representation, warranty,
covenant, or agreement prior to its expiration date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">21.2</TD><TD STYLE="text-align: justify">Indemnification Claims</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">Indemnification by ABVC. Effective as of the Completion Date, subject to the limitations set forth in
Section&nbsp;21.1 and Section&nbsp;21.3, ABVC shall be responsible for, shall pay on a current basis, and hereby agree to defend, indemnify,
hold harmless, and forever release Lucidaim, the Affiliates of Lucidaim, and each of their respective equity holders, directors, officers,
managers, employees, attorneys, consultants, agents, and representatives (collectively, the &ldquo;Lucidaim <B>Indemnified Parties</B>&rdquo;)
from and against any and all Liabilities, whether or not incurred in the investigation or defense of any of the same or in asserting,
preserving, or enforcing any of their respective rights hereunder, arising from, based upon, related to, or associated with: (A) any misrepresentation
or breach of any representation or warranty made by ABVC in this Agreement, provided a claim for such breach is made in writing before
the expiration of the period set forth in Section&nbsp;21.1; (B) the breach or non-performance of any covenant or obligation required
by this Agreement to be observed or performed by ABVC; or (C) any Excluded Liabilities of ABVC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Indemnification by Lucidaim. Effective as of the Completion Date, subject to the limitations set forth
in Section&nbsp;21.1 and Section&nbsp;21.3, Lucidaim shall be responsible for, shall pay on a current basis, and hereby agree to defend,
indemnify, hold harmless, and forever release ABVC, the Affiliates of ABVC, and each of their respective equity holders, directors, officers,
managers, employees, attorneys, consultants, agents, and representatives (collectively, the &ldquo; <B>ABVC Indemnified Parties</B>&rdquo;)
from and against any and all Liabilities, whether or not incurred in the investigation or defense of any of the same or in asserting,
preserving, or enforcing any of their respective rights hereunder, arising from, based upon, related to, or associated with: (A) any misrepresentation
or breach of any representation or warranty made by Lucidaim in this Agreement, provided a claim for such breach is made in writing before
the expiration of the period set forth in Section&nbsp;21.1; (B) the breach or non-performance of any covenant or obligation required
by this Agreement to be observed or performed by Lucidaim; or (C) any Excluded Liabilities of Lucidaim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">21.3</TD><TD STYLE="text-align: justify">Limitations on Indemnification</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify; text-indent: 0in">Rights to indemnification
under Section&nbsp;21.2 are subject to the following limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained
in this Agreement to the contrary, no Indemnifying Party shall have any liability pursuant to Section&nbsp;21.2(a)(A), Section&nbsp;21.2(b)(A),
or Section 21.2(c)(A), as the case may be, (A) for any individual Liability unless the amount of such Liability exceeds JPY 500,000
(the &ldquo;<B>Individual Indemnity Threshold</B>&rdquo;) and (B) until and unless the aggregate amount of all Liabilities (each of which
Liability having exceeded the Individual Indemnity Threshold) exceeds JPY 2,000,000 (the &ldquo;<B>Indemnity Deductible</B>&rdquo;),
and then only to the extent such Liabilities exceed the Indemnity Deductible.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Except for Liabilities paid in connection with a Third-Party Claim (as hereinafter defined), none of the
Indemnified Parties shall be entitled to recover from the Parties or their respective Affiliates, any special, indirect, consequential,
punitive, exemplary, remote, or speculative damages (including damages for lost profits of any kind) arising under or in connection with
this Agreement or the transactions contemplated hereby, except to the extent any such Person suffers such damages to a Third Party, which
damages to a Third Party (including costs of defense and reasonable attorneys&rsquo; fees incurred in connection with defending against
such damages) shall not be excluded by this provision as to recovery hereunder. Subject to the preceding sentence, ABVC, on behalf of
each of the ABVC Indemnified Parties, and Lucidaim, on behalf of each of the Lucidaim Indemnified Parties, waives any right to recover
any special, indirect, consequential, punitive, exemplary, remote, or speculative damages (including damages for lost profits of any kind)
arising in connection with or with respect to this Agreement or the transactions contemplated hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">21.4</TD><TD STYLE="text-align: justify">Procedures</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt"><B>(a)</B></TD><TD STYLE="text-align: justify">Notice. To make a claim for indemnification under this Agreement, an Indemnified Party shall promptly
notify the Person from whom indemnity is sought (the &ldquo;<B>Indemnifying Party</B>&rdquo;) in writing of its claim under Section&nbsp;21.2,
including the specific details of and specific basis under this Agreement for its claim (the &ldquo;<B>Claim Notice</B>&rdquo;). In the
event that the claim for indemnification is based upon a claim by a Third Party against the Indemnified Party (a &ldquo;<B>Third-Party
Claim</B>&rdquo;), the Indemnified Party shall provide its Claim Notice promptly after the Indemnified Party has actual knowledge of the
Third-Party Claim and shall enclose a copy of all papers (if any) served with respect to the Third-Party Claim; provided that the failure
of any Indemnified Party to give notice of a Third-Party Claim as provided in Section 21.3(d) shall not relieve the Indemnifying Party
of its obligations under Section&nbsp;21.2, except to the extent such failure results in insufficient time being available to permit the
Indemnifying Party to effectively defend against the Third-Party Claim or otherwise materially prejudices the Indemnifying Party&rsquo;s
ability to defend against the Third-Party Claim. In the event that the claim for indemnification is based upon an inaccuracy or a breach
of a representation, warranty, covenant, or agreement, the Claim Notice shall specify the representation, warranty, covenant, or agreement
that was inaccurate or breached.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">Defense and Settlement of Claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(i)</TD><TD STYLE="text-align: justify">In the case of a claim for indemnification based upon a Third-Party Claim, the Indemnifying Party shall
have thirty (30) days from its receipt of the Claim Notice to notify the Indemnified Party whether it admits or denies its obligation
to defend and indemnify the Indemnified Party against such Third-Party Claim at the sole cost and expense of the Indemnifying Party. The
Indemnified Party is authorized, prior to and during such thirty (30) day period, at the expense of the Indemnifying Party, to file any
motion, answer, or other pleading that it shall deem necessary or appropriate to protect its interests or those of the Indemnifying Party
and that is not prejudicial to the Indemnifying Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(ii)</TD><TD STYLE="text-align: justify">If the Indemnifying Party admits its obligation to defend and indemnify the Indemnified Party against
a Third-Party Claim, it shall have the right and obligation diligently to defend and indemnify, at its sole cost and expense, the Indemnified
Party against such Third-Party Claim. The Indemnifying Party shall have full control of such defense and proceedings, including any compromise
or settlement thereof. If requested by the Indemnifying Party, the Indemnified Party agrees to cooperate in contesting any Third-Party
Claim that the Indemnifying Party elects to contest. The Indemnified Party may participate in, but not control, at its own expense, any
defense or settlement of any Third-Party Claim controlled by the Indemnifying Party pursuant to this Section&nbsp;21.4. An Indemnifying
Party shall not, without the written consent of the Indemnified Party (which shall not be unreasonably withheld, denied, conditioned,
or delayed), (i) settle any Third-Party Claim or consent to the entry of any judgment with respect thereto that does not include an unconditional
written release of the Indemnified Party from all Liability in respect of such Third-Party Claim or (ii) settle any Third-Party Claim
or consent to the entry of any judgment with respect thereto in any manner that may materially and adversely affect the Indemnified Party
(other than as a result of money damages covered by the indemnity).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.3pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 35.4pt">(iii)</TD><TD STYLE="text-align: justify">If the Indemnifying Party does not admit its obligation or admits its obligation to defend and indemnify
the Indemnified Party against a Third-Party Claim, but fails diligently to prosecute, indemnify against, or settle such Third-Party Claim,
then the Indemnified Party shall have the right to defend against the Third-Party Claim at the sole cost and expense of the Indemnifying
Party, with counsel of the Indemnified Party&rsquo;s choosing, subject to the right of the Indemnifying Party to admit its obligation
and assume the defense of the Third-Party Claim at any time prior to settlement or final determination thereof. If settlement has been
offered and the Indemnifying Party has not yet admitted its obligation to defend and indemnify the Indemnified Party against a Third-Party
Claim, the Indemnified Party shall send written notice to the Indemnifying Party of any proposed settlement and the Indemnifying Party
shall have the option for ten (10) days following receipt of such notice to (i) admit in writing its obligation to indemnify the Indemnified
Party from and against the liability and consent to such settlement, (ii) if liability is so admitted, reject, in its reasonable judgment,
the proposed settlement, or (iii) deny liability. Any failure by the Indemnifying Party to respond to such notice shall be deemed to be
an election under subsection (iii), above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">Non-Third-Party Claims. In the case of a claim for indemnification not based upon a Third-Party Claim,
the Indemnifying Party shall have thirty (30) days from its receipt of the Claim Notice to (A) cure the Liabilities complained of, (B)
admit its liability for such Liabilities, or (C) dispute the claim for such Liabilities. If the Indemnifying Party does not notify the
Indemnified Party within such thirty (30)-day period that it has cured the Liabilities or that it disputes the claim for such Liabilities,
the Indemnifying Party shall be deemed to have disputed the claim for such Liabilities.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">22.</TD><TD STYLE="text-align: justify">Counterparts</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement may
be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures to such counterparts
and to this Agreement were upon the same instrument.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">23.</TD><TD STYLE="text-align: justify">Further assurance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each Party agrees
(at its own cost) to perform (or procure the performance of) all further acts and things, and execute and deliver (or procure the execution
and delivery of) such further documents, as may be required by law or as the other Parties may reasonably require, whether on or after
Completion, to implement and/or give effect to this Agreement and the transaction contemplated by this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">24.</TD><TD STYLE="text-align: justify">Waiver</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Any of the terms,
covenants, representations, warranties, or conditions hereof may be waived only by a written instrument executed and delivered by or on
behalf of the Party waiving compliance. No course of dealing on the part of any Party or its officers, directors, managers, employees,
agents, or representatives, and no failure by any Party to exercise any of its rights under this Agreement, shall, in any such case, operate
as a waiver thereof or affect in any way the right of such Party at a later time to enforce the performance of such provision. No waiver
by any Party of any condition, or any breach of any term, covenant, representation, or warranty contained in this Agreement, in any one
or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or a waiver of
any other condition or of any breach of any other term, covenant, representation, or warranty. The rights of the Parties under this Agreement
shall be cumulative, and the exercise or partial exercise of any such right shall not preclude the exercise of any other right.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">25.</TD><TD STYLE="text-align: justify">Entire agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement (and
any other agreements contemplated hereby or thereby) constitutes the entire agreement among the Parties with respect to the subject matter
of this Agreement and supersedes all prior agreements, understandings, and negotiations, both written and oral, among the Parties with
respect to the subject matter hereof. No representation, inducement, promise, understanding, condition, or warranty not set forth in this
Agreement has been made or relied upon by any Party. This Agreement is not intended to confer upon any Person other than the Parties hereto
any rights or remedies hereunder. The Exhibits to this Agreement are and shall be deemed to be a part of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">26.</TD><TD STYLE="text-align: justify">Notices</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">26.1</TD><TD STYLE="text-align: justify">Save as otherwise provided in this Agreement, any notice, demand or other communication (&ldquo;<B>Notice</B>&rdquo;)
to be given by any Party under, or in connection with, this Agreement shall be in writing and signed by or on behalf of the Party giving
it. Any Notice shall be served by sending it by fax to the number set out in Section 26.2, or delivering it by hand to the address set
out in Section 26.2 and in each case marked for the attention of the relevant Party set out in Section 26.2 (or as otherwise notified
from time to time in accordance with the provisions of this Section 26). Any Notice so served by fax or hand shall be deemed to have
been duly given or made as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">if sent by fax, at the time of transmission; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">in the case of delivery by hand, when delivered,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">provided that in
each case where delivery by fax or by hand occurs after 6 pm on a Business Day or on a day which is not a Business Day, service shall
be deemed to occur at 9 am on the next following Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">References to time
in this Section are to local time in the country of the addressee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">26.2</TD><TD STYLE="text-align: justify">The addresses and fax numbers of the Parties for the purpose of Section 26.1 are as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">(a) ABVC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Address: 44370 Old
Warm Springs Blvd., Fremont, CA 94538, USA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">For the attention
of: Andy An</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">(b) Lucidaim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">Fax:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in">For the attention
of: Toru Seo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">(c) Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">Address: 3-8-3 Nihonbashi
Honcho, Chuo-ku, Tokyo 103-0023, Japan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">For the attention
of:&nbsp;Toru Seo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">26.3</TD><TD STYLE="text-align: justify">A Party may notify all other Parties to this Agreement of a change to its name, relevant addressee, address
or fax number for the purposes of this Section 26, provided that such notice shall only be effective on:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">the date specified in the notification as the date on which the change is to take place; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">if no date is specified or the date specified is less than five (5) Business Days after the date on which
notice is given, the date following five (5) Business Days after notice of any change has been given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">26.4</TD><TD STYLE="text-align: justify">In proving service it shall be sufficient to prove that the envelope containing such notice was properly
addressed and delivered to the address shown thereon or that the facsimile transmission was made and a facsimile confirmation report was
received, as the case may be.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">27.</TD><TD STYLE="text-align: justify">Costs</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">27.1</TD><TD STYLE="text-align: justify">Subject to any Sections entitling any Party to recover its costs from any other Party if particular conditions
are not fulfilled, each of the Parties shall be responsible for its own legal, accountancy and other costs, charges and expenses incurred
in connection with the negotiation, preparation and implementation of this Agreement and any other agreement incidental to or referred
to in this Agreement unless otherwise agreed by the Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">27.2</TD><TD STYLE="text-align: justify">Unless otherwise agreed by the Parties, each Party undertakes to the others that the Company has not paid
and will not pay (in connection with the subscription contemplated by this Agreement) any legal, accounting or other professional charges,
fees, expenses or commissions relating to the subscription of the Shares including any such costs incurred in connection with any investigation
of the affairs of the Company or the negotiation, preparation, execution and carrying into effect of this Agreement.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">28.</TD><TD STYLE="text-align: justify">No Third-Party Beneficiaries</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Parties and
this Agreement do not confer any rights or remedies upon any Person other than the Parties to this Agreement and their respective successors
and permitted assigns.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">29.</TD><TD STYLE="text-align: justify">Amendments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement may
be amended, restated, supplemented, or otherwise modified only by an instrument in writing executed and delivered by all Parties and expressly
identified as an amendment, restatement, supplement, or modification.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">30.</TD><TD STYLE="text-align: justify">Continuing effect</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each provision of
this Agreement shall continue in full force and effect after Completion, except to the extent that a provision has been fully performed
on or before Completion.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">31.</TD><TD STYLE="text-align: justify">Illegality and Severability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">If application of
any one or more of the provisions of this Agreement shall be unlawful under Applicable Law, then the Parties will attempt in good faith
to make such alternative arrangements as may be legally permissible and that carry out as nearly as practicable the terms of this Agreement.
Should any portion of this Agreement be deemed unenforceable by a court of competent jurisdiction, the remaining portions hereof shall
remain unaffected and be interpreted as if such unenforceable portion had been initially deleted.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">32.</TD><TD STYLE="text-align: justify">Successors and Assigns</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">No Party shall assign
this Agreement or any of its rights in and to this Agreement without the prior written approval of the other Party. Subject to the preceding
sentence, the provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors
and assigns.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">33.</TD><TD STYLE="text-align: justify">Governing law and Arbitration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">33.1</TD><TD STYLE="text-align: justify">Governing law</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement shall
be governed by and construed in accordance with the laws of Japan without regard to principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">33.2</TD><TD STYLE="text-align: justify">Arbitration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">All
disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International
Chamber of Commerce (&ldquo;ICC&rdquo;) by one or more arbitrators appointed in accordance with the said Rules. </FONT>The seat of arbitration
shall be Japan.&nbsp;Any arbitration<FONT STYLE="background-color: white">&nbsp;proceeding will proceed in</FONT> Tokyo, Japan. The arbitration
proceedings will be conducted in English, and the award will be rendered in writing in English.&nbsp;Unless otherwise ordered by the
arbitrator, each Party shall bear its own costs and fees, including attorneys&rsquo; fees and expenses.&nbsp;The Parties agree to treat
any award made by the arbitral tribunal as final and binding upon them and immediately enforceable against them, and undertake not to
exercise or seek to exercise any right of appeal or other challenge against such final award before any court or jurisdiction.&nbsp;Notwithstanding
the foregoing, nothing in this Agreement shall prohibit the Parties from seeking any preliminary, emergency or interim injunctive relief
in any court of competent jurisdiction or from the ICC or arbitrators.&nbsp;Judgment upon any award rendered by the arbitrator may be
entered by any court having jurisdiction over the Party against whom enforcement is sought.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">34.</TD><TD STYLE="text-align: justify">Advice of Counsel</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Parties have
each consulted counsel of their choice regarding this Agreement and each acknowledges and agrees that this Agreement shall not be deemed
to have been drafted by one Party or another and shall be construed accordingly.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">35.</TD><TD STYLE="text-align: justify">Captions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The captions in
this Agreement are included for convenience of reference only and shall be ignored in the construction or interpretation hereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">36.</TD><TD STYLE="text-align: justify">Governing language</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The official text
of this Agreement and any notices given hereunder shall be in English. In the event of any dispute concerning the construction or interpretation
of this Agreement, reference shall be made only to this Agreement as written in English and not to any translation into any other language.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[SIGNATURES ON FOLLOWING PAGE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the Parties
to this Agreement have caused this Agreement to be duly executed by their respective authorized representatives on the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ABVC BioPharma, Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify">/s/ Eugene Jiang</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify">Eugene Jiang</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chairman</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the Parties
to this Agreement have caused this Agreement to be duly executed by their respective authorized representatives on the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>Lucidaim Co., Ltd.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify">/s/ Toru Seo</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify">Toru Seo</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Representative Director</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the Parties
to this Agreement have caused this Agreement to be duly executed by their respective authorized representatives on the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>BioLite Japan K.K</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify">/s/Toru Seo</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify">Toru Seo</TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Representative Director</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan K.K.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of Incorporation</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 December 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place of Incorporation</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered office</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-8-3 Nihonbashi Honcho, Chuo-ku, Tokyo </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toru Seo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative Director</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toru Seo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-42-12 Musashidai, Fuchu-shi, Tokyo </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Authorized Shares</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000 shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Issued Shares</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,049 ordinary share</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount of Share Capital</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JPY 30,490,000 </FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Conditions Precedent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Completion is conditional on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.</TD><TD STYLE="text-align: justify">All government, governmental, supranational or trade agency or regulatory body consents (including the
expiry of any period following a notification such that consent is deemed to be given or no consent is required) which are required for
the Transaction being obtained in terms satisfactory to the Shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Reserved Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.</TD><TD STYLE="text-align: justify">Any amendment to the articles of association of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.</TD><TD STYLE="text-align: justify">Any change in the name of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Accounting and Financial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.</TD><TD STYLE="text-align: justify">Any alteration to the Company&rsquo;s accounting reference date or, other than as required by law, the
Japanese GAAP.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.</TD><TD STYLE="text-align: justify">Save as required by Section 9, the declaration or payment of any dividend or other distribution by the
Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Commercial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.</TD><TD STYLE="text-align: justify">Any material change in the nature of the Business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.</TD><TD STYLE="text-align: justify">The approval or amendment of the Business Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.</TD><TD STYLE="text-align: justify">Any arrangement for the disposal of the whole or substantially the whole of the assets of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Employment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.</TD><TD STYLE="text-align: justify">The determination of the remuneration, if any, of the directors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Insolvency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.</TD><TD STYLE="text-align: justify">Unless otherwise expressly provided for in this Agreement, the making of any compromise or arrangement
with the Company&rsquo;s creditors, any application for the appointment of a receiver or an administrator over the Company&rsquo;s assets
or the winding up of the Company (whether voluntarily or compulsorily).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 4</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Part 1: Roulette Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">To:</TD><TD STYLE="text-align: justify"><B><I>[Insert name of Shareholder<BR>
and contact details from<BR>
Section 26 of the Agreement</I></B><I>]</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>[Date]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Dear Sirs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Roulette Notice</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We refer to the Joint Venture
Agreement dated [<B><I>insert date</I></B>] (&ldquo;<B>Agreement</B>&rdquo;) and made between yourselves and ourselves and to the Deadlock
provisions contained in Section 14 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We hereby:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">offer to purchase all (but not some only) of the shares in the capital of [<B><I>insert name</I></B>]
Limited (the &ldquo;<B>Company</B>&rdquo;) held by you, at the price of &pound;[<B><I>insert amount</I></B>] per share; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">in the alternative, offer to sell to you all (but not some only) of the shares held by us in the capital
of the Company, at that price per share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">You may accept either of the
above offers by service on us of an Acceptance Notice pursuant to Section 14 of the Agreement. Completion of the sale and purchase of
the shares contemplated by Section&nbsp;14 of the Agreement shall take place at [<B><I>insert location</I></B>] on [<B><I>insert time
and date</I></B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In the event that you accept
the offer set out in paragraph (b), then details of our bank account into which the aggregate consideration should be transferred on completion
are [<B><I>insert name</I></B>] Bank plc, [<B><I>insert address</I></B>], Sort Code [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
Account Number [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>[<I>Name</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For and on behalf of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[Shareholder]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Part 2: Acceptance Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">To:</TD><TD STYLE="text-align: justify"><B><I>[Insert name of Shareholder<BR>
and contact details from<BR>
Section 26 of the Agreement</I></B><I>]</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>[Date]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Dear Sirs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Acceptance Notice</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We refer to the Joint Venture
Agreement dated [<B><I>insert date</I></B>] (&ldquo;<B>Agreement</B>&rdquo;) and made between yourselves and ourselves (and, in particular,
to the Deadlock provisions contained in Section 14 of the Agreement) and to the Roulette Notice dated [<B><I>insert date</I></B>]. This
letter is the Acceptance Notice referred to in Section 14.5 of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[We hereby accept your offer
to purchase all (but not some only) of the shares in the capital of [<B><I>insert name</I></B>] Limited held by us, at the price of &pound;[<B><I>insert
amount</I></B>] per share]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[We hereby accept your offer
to sell to us all (but not some only) of the shares held by you in the capital of [<B><I>insert name</I></B>] Limited, at the price of
&pound;[<B><I>insert amount</I></B>] per share.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Yours faithfully</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>[<I>Name</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">For and on behalf of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[Shareholder]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule 5</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Share Transfer Provisions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.</TD><TD STYLE="text-align: justify">Transfer terms</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.1</TD><TD STYLE="text-align: justify">Any sale and/or transfer of Shares pursuant to this Agreement shall be on terms that those Shares:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">are transferred with full legal and beneficial title free from all Encumbrances; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">are transferred with the benefit of all rights attaching to them as at the date of the agreement to sell
or transfer the Shares or of the relevant Roulette Notice, Acceptance Notice, Action Notice or Bid, as appropriate but without the benefit
of any other warranties or representations whatsoever.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.</TD><TD STYLE="text-align: justify">Approval</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Directors shall
promptly register any transfer of Shares permitted by this Agreement and each Shareholder shall procure that each Director appointed by
it shall comply with this obligation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.</TD><TD STYLE="text-align: justify">Registration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Parties shall
procure that a transfer of Shares is not approved for registration unless this Agreement and the Articles have been complied with.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.</TD><TD STYLE="text-align: justify">Further assurance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">Each Party shall
do all things and carry out all acts which are reasonably necessary to effect the transfer of the shares in accordance with the terms
of this Agreement in a timely fashion.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.</TD><TD STYLE="text-align: justify">Return of documents, etc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">On ceasing to be
a Shareholder, a Shareholder must use reasonable endeavours to hand over to the Company, save to the extent required by law, material
correspondence, budgets, Business Plans, schedules, documents and records relating to the Business held by it or an Associated Company
or any third party which has acquired such matter through that Shareholder and shall not keep any copies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.</TD><TD STYLE="text-align: justify">Loans, borrowings, guarantees and indemnities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.1</TD><TD STYLE="text-align: justify">Upon a transfer of all the Shares held by a Shareholder</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(a)</TD><TD STYLE="text-align: justify">the continuing Shareholder shall procure that all loans, borrowings and indebtedness in the nature of
borrowings outstanding owed by the Company to a transferring Shareholder (together with any accrued interest) are either assigned to the
continuing Shareholder for such value as may be agreed between the transferring Shareholder and the continuing Shareholder, or failing
agreement with the continuing Shareholder, are repaid by the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(b)</TD><TD STYLE="text-align: justify">all loans, borrowings and indebtedness in the nature of borrowings outstanding owed by that transferring
Shareholder to the Company shall be repaid; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(c)</TD><TD STYLE="text-align: justify">the continuing Shareholder shall use all reasonable endeavours (but without involving any financial obligation
on its part) to procure the release of any guarantees, indemnities, security or other comfort given by the transferring Shareholder to
or in respect of the Company or its Business and, pending such release, shall indemnify the transferring Shareholder in respect of them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.2</TD><TD STYLE="text-align: justify">Any assumption of the obligations of a transferring Shareholder by the continuing Shareholder is without
prejudice to the right of the continuing Shareholder and/or the Company to claim from the transferring Shareholder in respect of liabilities
arising prior to the completion date of the transfer of Shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.</TD><TD STYLE="text-align: justify">Assumption of obligations</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
shall procure that no person shall be registered by the Company as the holder of any Shares unless it first enters into agreement to be
bound by all the terms of this Agreement as if it had been a signatory.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.</TD><TD STYLE="text-align: justify">Waiver of pre-emption rights</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The Shareholders
waive their pre-emption rights to the transfer of Shares contained in this Agreement and the Articles to the extent necessary to give
effect to this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.</TD><TD STYLE="text-align: justify">Removal of appointees</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.1</TD><TD STYLE="text-align: justify">If a Shareholder ceases to be a Shareholder it shall immediately upon transfer of its Shares procure the
resignation of all its appointees to the Directors. If the continuing Shareholder requests, it shall do all such things and sign all such
documents as may otherwise be necessary to procure the resignation or dismissal of such persons in a timely manner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.2</TD><TD STYLE="text-align: justify">Those resignations shall take effect without any liabilities on the Company for compensation for loss
of office or otherwise except to the extent that the liability arises in relation to a service contract with a Director who was acting
in an executive capacity. Any Shareholder removing a Director appointed by it shall fully indemnify and hold harmless the other Shareholder
and the Company from and against any claim for unfair or wrongful dismissal arising out of such removal.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.</TD><TD STYLE="text-align: justify">Interest</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">The purchase moneys
shall, to the extent that they are not delivered to the Selling Shareholder on or before the appropriate completion date, bear interest
against the purchasing Party at the rate of 4 per cent. over the base lending rate from time to time of Mizuho Bank, Ltd. calculated on
a daily basis from such date until the Selling Shareholder is reimbursed by the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Exhibit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM OF SHARE TRANSFER AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">As attached</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Share Transfer Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This Agreement <FONT STYLE="font-weight: normal">is
dated October 6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>ABVC BioPharma, Inc.</B>,
a Nevada corporation with its principal place of business located at 44370 Old Warm Springs Blvd., Fremont, CA 94538, U.S.A. (&ldquo;<B>ABVC</B>&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Lucidaim Co., Ltd.</B>, a
Japanese corporation with its principal place of business located at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&ldquo;<B>Lucidaim</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">ABVC and Lucidaim are referred
to herein individually as a &ldquo;<B>Party</B>&rdquo; and, collectively, the &ldquo;<B>Parties</B>&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recitals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt">A.</TD><TD STYLE="text-align: justify">WHEREAS, BioLite Japan K.K. is a private limited company (a Japanese <I>Kabushiki Kaisha</I>) incorporated
on 18 December 2018 with its principal place of business located at 3-8-3 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan (&ldquo;<B>Company</B>&rdquo;)
and at the date of this Agreement has an issued share capital of JPY thirty million four hundred ninety thousand (30,490,000) with three
thousand forty nine (3,049) ordinary shares. One thousand five hundred one (1,501) ordinary shares out of such three thousand forty nine
(3,049) ordinary shares have been issued nil paid and are held by Lucidaim and the remaining one thousand five hundred forty eight (1,548)
ordinary shares have been issued nil paid and are held by ABVC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.5pt">B.</TD><TD STYLE="text-align: justify">Lucidaim desires<FONT STYLE="background-color: white">&nbsp;to acquire from ABVC ordinary shares of the
Company (</FONT>&ldquo;<B>Shares</B>&rdquo;<FONT STYLE="background-color: white">), and ABVC desires to transfer the Shares to Lucidaim,
all pursuant to and in accordance with the terms and conditions set forth in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NOW, THEREFORE, in consideration
of the mutual agreements and undertakings contained herein, the Parties, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Share Transfer</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">On the terms of this agreement and with effect from the date of this Agreement, ABVC shall transfer and
Lucidaim shall acquire, for no consideration, fifty four (54) Shares with full title guarantee free from all any interest or equity of
any person (including any right to acquire, option or right of pre-emption) or any mortgage, charge, pledge, lien, assignment, hypothecation,
security interest, title retention or any other security agreement or arrangement (&ldquo;<B>Encumbrances</B>&rdquo;) and together with
all rights that attach (or may in the future attach) to the Shares including, in particular, the right to receive all dividends and distributions
declared, made or paid on or after the date of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">ABVC represents and warrants to, and covenants with, Lucidaim that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(a)</TD><TD STYLE="text-align: justify">it has the right to transfer the Shares on the terms set out in this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(b)</TD><TD STYLE="text-align: justify">it shall do all it can, at its own cost, to give Lucidaim the full legal and beneficial title to the Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(c)</TD><TD STYLE="text-align: justify">it transfers the Shares free from all Encumbrances;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(d)</TD><TD STYLE="text-align: justify">there is no right to require the Company to issue any share capital or create an Encumbrance affecting
any unissued shares or debentures or other unissued securities of the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(e)</TD><TD STYLE="text-align: justify">no commitment has been given to create an Encumbrance affecting the Shares (or any unissued shares or
debentures or other unissued securities of the Company), or for the Company to issue any share capital and no person has claimed any rights
in connection with any of those things.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">Each Party shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(a)</TD><TD STYLE="text-align: justify">Conduct <FONT STYLE="background-color: white">transactions contemplated under this Agreement in compliance
with any Applicable Laws including without limitation the Companies Act of Japan (</FONT>Act No. 86 of 2005<FONT STYLE="background-color: white">);
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34.95pt"></TD><TD STYLE="width: 41.55pt">(b)</TD><TD STYLE="text-align: justify">At the date of this Agreement, deliver a certified copy of the resolutions adopted by the board of directors,
or any other applicable organ, of the Party authorizing the <FONT STYLE="background-color: white">transactions contemplated under this
Agreement</FONT> and the execution and delivery by the officers specified in the resolution[s] of this agreement, and any documents necessary
to transfer, or acquire as applicable, the Shares in accordance with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: justify; text-indent: -41.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">Taxes, Costs and Expenses</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.75pt; text-align: justify; text-indent: -28.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 28.05pt">(a)</TD><TD STYLE="text-align: justify">Except as<FONT STYLE="background-color: white">&nbsp;otherwise provided for in this Agreement, each of
ABVC and Lucidaim shall bear all </FONT>local, national and foreign taxes and assessments, including all interest, penalties and additions
with respect thereto, <FONT STYLE="background-color: white">incurred by or levied on it in connection with the transactions contemplated
under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.75pt; text-align: justify; text-indent: -28.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 28.05pt">(b)</TD><TD STYLE="text-align: justify">Except as<FONT STYLE="background-color: white">&nbsp;expressly provided otherwise herein, each Party shall
bear its own costs and expenses (including advisory fees) incurred in the negotiation, preparation and completion of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.75pt; text-align: justify; text-indent: -28.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.</TD><TD STYLE="text-align: justify">Governing law and Arbitration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.1</TD><TD STYLE="text-align: justify">Governing law</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0in">This Agreement shall
be governed by and construed in accordance with the laws of Japan without regard to principles of conflicts of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.2</TD><TD STYLE="text-align: justify">Arbitration</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">All disputes arising
out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce
(&ldquo;ICC&rdquo;) by one or more arbitrators appointed in accordance with the said Rules. The seat of arbitration shall be Japan.&nbsp;Any
arbitration proceeding will proceed in Tokyo, Japan. The arbitration proceedings will be conducted in English, and the award will be
rendered in writing in English.&nbsp;Unless otherwise ordered by the arbitrator, each Party shall bear its own costs and fees, including
attorneys&rsquo; fees and expenses.&nbsp;The Parties agree to treat any award made by the arbitral tribunal as final and binding upon
them and immediately enforceable against them, and undertake not to exercise or seek to exercise any right of appeal or other challenge
against such final award before any court or jurisdiction.&nbsp;Notwithstanding the foregoing, nothing in this Agreement shall prohibit
the Parties from seeking any preliminary, emergency or interim injunctive relief in any court of competent jurisdiction or from the ICC
or arbitrators.&nbsp;Judgment upon any award rendered by the arbitrator may be entered by any court having jurisdiction over the Party
against whom enforcement is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.</TD><TD STYLE="text-align: justify">Counterparts</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">This Agreement may be signed
in any number of counterparts, each of which shall be an original, with the same effect as if the signatures to such counterparts and
to this Agreement were upon the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURES ON FOLLOWING PAGE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the Parties
to this Agreement have caused this Agreement to be duly executed by their respective authorized representatives on the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ABVC BioPharma, Inc.</B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 35%; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: justify">/s/ Eugene Jiang</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Eugene Jiang</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Title:</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Chairman</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Execution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">IN WITNESS WHEREOF, the Parties
to this Agreement have caused this Agreement to be duly executed by their respective authorized representatives on the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>Lucidaim Co., Ltd.</B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 35%; text-align: justify">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: justify">/s/ Toru Seo</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Toru Seo</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Title:</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Representative Director</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>abvc-20211008_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>abvc-20211008_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20211008.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>abvc-20211008.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWaWJ6aPtzplyaZlBtmdxbVna/ywjPoNhRC3fsNcWQcQH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ABVC="http://abvcpharma.com/20211008" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20211008">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20211008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20211008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>ea148616-8k_abvcbiophar_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20211008.xsd" xlink:type="simple"/>
    <context id="From2021-10-08to2021-10-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-10-08to2021-10-08">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-10-08to2021-10-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-10-08to2021-10-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-10-08to2021-10-08">2021-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-10-08to2021-10-08">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-10-08to2021-10-08">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-10-08to2021-10-08">333-91436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-10-08to2021-10-08">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-10-08to2021-10-08">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-10-08to2021-10-08">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-10-08to2021-10-08">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-10-08to2021-10-08">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-10-08to2021-10-08">(510)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-10-08to2021-10-08">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-10-08to2021-10-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-10-08to2021-10-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-10-08to2021-10-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-10-08to2021-10-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-10-08to2021-10-08">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139747574979848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  08,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-91436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $Z(2%,'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 3HA(4\;#YDWN    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 3HA(4YE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !.B$A3
M8#\BL=(#  !D#@  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 3HA(4Y^@&_"Q @  X@P   T
M     ( !%0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !.B$A3EXJ[',
M   3 @  "P              @ 'Q#@  7W)E;',O+G)E;'-02P$"% ,4
M" !.B$A3JL0B%C,!   B @  #P              @ ':#P  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 3HA(4R0>FZ*M    ^ $  !H
M ( !.A$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M3HA(4V60>9(9 0  SP,  !,              ( !'Q(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  :1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea148616-8k_abvcbiophar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea148616-8k_abvcbiophar.htm">ea148616-8k_abvcbiophar.htm</File>
    <File>abvc-20211008.xsd</File>
    <File>abvc-20211008_lab.xml</File>
    <File>abvc-20211008_pre.xml</File>
    <File>ea148616ex10-1_abvcbiopharma.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea148616-8k_abvcbiophar.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea148616-8k_abvcbiophar.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20211008_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20211008_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20211008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20211008",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea148616-8k_abvcbiophar.htm",
      "contextRef": "From2021-10-08to2021-10-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abvcpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea148616-8k_abvcbiophar.htm",
      "contextRef": "From2021-10-08to2021-10-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001213900-21-052090-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-052090-xbrl.zip
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MI;+VDC5XPJ1"S'^&#U1)F ?OP\SY#$HJH0<9E!30 "_@)/:= 1]![=#X/:\
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M*'.D@K)&2?E\IAIF^UD^*N+6ZXW7Z41R__*02B&4,$J"%[#6,.2]?E3C/9!
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M<X&^REK$ CP)+]CG@6BG4XA'2M\M=(.E7-(I?C./5@Z!^&%$TCR=0T=J(H-
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M;GJJY>8<WZ1I7Z&!Q\J0Q&'7^1&J]8@K&^*$3JSWT?MV2)\E13'%@5,"AX>
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M$P-W GDI9US(2++RRX]X;]X\K:'+P$[_4JU,UV5#>\-W)6&RT>EY$2LF?JZ
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MQ 4WBNH01+5GBA\D"<M(T.1E\XADPK6-',$P8D;\M,(YI9OE\159L6&<2Z5
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M)6"&J-B[@KV 1V>@UE$!?Q^@6%==UW"BO==VGIVF:X2#_BWZ3[E,/;JJR2Z
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MRN'>5((8A<]U7F"#T;7:6.?>.">,"%?LE##_*+Q$@F%9WT/WJ%*S"CN#D-Z
M]S<:E,XD>>'_0N--)U;EM0*1\"*JBE80*%6**/&W<<K(,!5>XCJ-NNH>=%6_
MLHV_FJ-]C.HW"QL_$\JL<$]VQ(G+T>[&\"IW[LR3&D+Z$2+8X&<6XV8J*6KE
M&-O+$V<2_^"#W[!Y6V,L)V2V#6C,)=Z!+S$#-4C;M%$^Y;7]X39\E/4A6'W$
M_^G]R262I)[(Y'3,00*62XD!68K*48N;.E\'!V-<ONK:V%K=DBK268=@=F0M
MOI^(2U_68J<W5[4I'AW,#K&8"02ZN-*"-FM7[*L%2-X"CR>'=7->KU[BDQPL
MAMYBZ8+3*KY]QR4A0N3<,S%BVR391) 9LKS46\4>/ _<*LG0Z8T'W2OQY&3$
MX @&Y^DW@<$9%?(@6+Q5MUW1K&@C:P4NTM:"MRJXF:S<I@:%^CLWJ 95%%D$
MSDK5<P"#&$B"2*U*0CU794S_+(1K7AZ]K<[T9]3V ]>QWXGP]>3E;J5O33%,
MNV"R*HHD.Q;M/8JW(N'VAD1(8FGS*,N+!PGHS+!>P=EAD.=D?"AF@&<[9,RG
MV'S*X_[YE L,8U"KE,I?]'01W*^'-@0O$>NCK$;T77UH:V*MAV:I".LJU2FD
M>%RK"^2+NTK\3+HAP'!3!R].ZK(U@V/&4:B\?2,,<I'#-X9H[B%$TZ_<]F,3
MA5EE",:83:O+4U/$R3\K$V.%2$07H\9;X[BT6VH83"? 0[YJ4H=QFCV+=ZUV
M+*&FT*C!]<(*UX+OS_BG<4L.<DOVJVY\#0M-I7CE&L,(N.(CA_"UH515XW)T
MB7GK0,>;QT2)R4+2&(WC$);F2FTZT>R23;(H-_BHNAI3&#E# +:J7U-<#G?!
M7!$2OU'P5))!!C& =,<:#FR"#O&0#?.D)+*./.:ZI S4QMS%S)7/#Y#6#;!N
MY%?I*IHE#VJ\^<'54C/4XMHI\)HS0+9>GRDXM$!+' C%RL0 J3Y$53?4\K3O
MHE;G2;]:'5>%F2I=25T,1*-]MP?3DYX ]F9N790&-9HD*$FAUY2"UDE>9J!9
MJ@YHK'DR3!XO"%>$)I.PA278Q2]@]O9,QXHKUD7??-"YSBY!(?\F1:P(Q2'Z
MAT:YB_%:&!,467X-SCTW@P5C6]I[E[G^K6%:%BPE#PLB=G07V>DCV!(;.?,=
MYH_Z@48N]8P*HH6$@($61)C@8?MNS (9EH0&FF$[S<[8S&TP$O>TWSGU MXH
M2DI:Y2J?/*J+^UZ\?D?4>1"@M8JKA_C8+!S*R@W&7>I :MN2)Q4$9<90T= 3
MWE"F?)(Y)>O; <DAB%OF>5L+*B+R FWL_?7\_/T8=;B'G=/OH(6=0]XF @BI
M"?Q=$U&/";%;AL>T=K:-8+1294I@K:H$HSF+D)LMT\+9I!#DF0O5/"74K#AP
M$:,B2?%-CXL$OXTK\KXE5B40(B="6"E>BR5'1?K374K3R?'COC4K)$[?FC3Q
M;MHI3"1+43]9^J3U&ALI6,N6I0 MVYGQLBI.,:HO0P[7)NZ.OA+CF1NXPPT+
MQ'!Q&1 CE1&DG=>A6'<*=QIEI:>L]!069.3-YXBBR'4\KY"?#LH2@6^2YGB*
M'=@S[-U*C([Z[J$7XWKW7>^>"\YU 1$%A<E,W,AQT0#APM<"W*%J:(/?K HF
M8G65#SX4,^SF>2>G([91L(W/OF-LX^@*]7&%^G7J^F*MJ$<7Z Y<H(X,Q1HK
MX;(*C.H&C=LE*HTR/OP1.5"O3<AC.OF75EEUM-E2VU5D\Z2U6V(M7<4LCIB0
M8N,=G!TWR,4]5D(N%P35"" D)"BS#,MJ[" \' -E4FLU.$3E67^!&DGXZ(0-
MP=#J"Z^NRD[A7W-I;$>M+"0H1Q_,5$PQMWRI=6&%7$1B]*2&L.!]5SSQP!^.
M5AB#E9W=Y,BHE1[7=__H2 UFN?NO-\97%'>;+<-%>_\.'5/^52_HK5?$?*Q*
M%"G\!=LTY*UJF4DV7JCUBFV0=89L;EO9.TR'D!:WP'2"_K;4')X=U\P(:1\"
MBF*NLXRA; [*%(Q@L*9&J1J$5/4L==EBUF::&\&VF2<*[]^EPI8R%+F%_X*Q
M6VM*+=1!!AG3-&T)5:@8V)#"=<Q3EG<9MTRATSDZK (+F\!!*[C;C& 84Z8#
M':T+LFX-OB+-53Q*[2"D-OQRSI@MRFI(>-WWFDYV.%\[R/6.O%O5U].)4=B$
MPN\:=WTPOZD,KKMS)KXQ-M0G-M2/?NE<I'7$E5R/*RF1VJ? L ;L R0-(D0=
MG2+IC $G=,X8PMW$0WY<5 P!0U#T?(Z;LS*%8-Y]@QJFO../V-HQ"C#.ZR:;
MC6Y!#J$R*&R8Q'*J#2"X_]UML'Z<05TX\=]M3FG<==?1G=7Z+;<)SRA=%QE\
M!Y7-.PD[DYESJD:?CL45][AKGO4#K;Z,<J[;P15;IZ 1A]*4^;O5=\_NIJB"
M=O2=!O%'/^CN:*NZ&&Y;A))^1_UO:#:X=@KNP@C1?=R0%]WXZ:2>':J:-)X<
M/<*P$*7@CQI18Z<C+Z887$))-*-"5[4<.&&GE5:)X;22L^+AXQ/X<SIY(2UB
M<^\\* [%&E/-Y-5(N3(82>X9W:S1%:) K9""D&K28W75);=KM;%BFG?%?D(,
M^3 Y/?XZ!/?:6NL.:QH%"I*D1":V1BV.)$TKYF=JY8M(14Z1M3")QCFP33.:
MNP;+U%04^F!,,==^!VDLOAA%UJ*5\X);,/#GN&"Q'C[4Z:L6]UZ'<N_.#M0^
M$^7+%#J[$K!4O=2E-$JORY??I7RG$VE [3(*PIU*2O["OLLT<0$<B"CJSVNP
M!W1#M _=RG#YJL<PZY64,)16T;44<.8P2U)W)^,QQ>C_W98CZM %[")B/0B6
M<G>_QIELSRF9*9LD":CX'V<DXZ  <Q?#/[-95&2*KI4^WU%F&\,KI[OP@9QI
M:I9KZ5 #DAO-*7"196EV.)W,N* ^YI1[Q!P-\O[O%1%\?!W5?E]#T]2S$=0H
MH,:3XV\"U3@&"^[^=#LY[A<M^*!1^3.9>Y!>:E#%Q5#BV=^M:0*+UR]@8%</
MF?'G(S70+FJ@1MT;MCX0<:^,\U;GN+H?0WD(O,^*\X9BV?PU2\LUN08^=:.!
MT=D[&D9VAVQ ?M5ZUD@Y/NS8#34"3+TXQ>)GY/+V/6'"/\_S-,!L<%@UM9C3
M!9G&E!8"B>LBXTK409O+?#H!%7#*T1)E0#SPTU-O R:RY9-C'QD-3YL#OV9$
M8*.HG,$;V"W8C*K1VNJB,HJGDY=P%[?/E8^WL3V/Q(WG= *8^]FF:KU$_G''
M3@E4E@D%GJD;] TI1YHX_+T,:R7V7]RNR9]EPKJ.ME=*5\\T6.US2_E!-X$)
MR[&K)SYHXW'7D!EFVA=@E824-0QTAMP<=&^N/,0O0F($CC?"."Q_^=;O4YQ4
MJ;1#*!3"/O'Z)?@1/(('[=!JP9306,1-(+HP@P7@N<)<C"ZTHXOL!?)JM9F<
M3G@J#Z3IY));C"I/BGJ1@HN9MG!QZ.Y,758-@IPKY8Y#"]Z\ULHTRKE56W()
M<T0-9&SWZ#2)T4,$$;8]/V%FYSA/X%DQM=B<><120[,K;"N(HZ>^753WIS!V
MHJB\.&:+%E1S5I\%> ^P=G/JT#ET OSO1&_VC!0.46\Z&LY[23 >1ZE=JXR\
MZW01[HJV,DHN%6HZ]#8#4=6(9*"^RAE\7W(#OYDVUZ)*DJM95YGKB55H([=&
M/G7J(^T%<22Z)X#)3U>@CHC^T+9KZKB@4>Q/3UE(#YEM"IPG@<*RX*C2I:&&
M9<<(F:G][/C==-)H0(_?4L]%R\&D"O-2BS0-F1-09Y<10CKD4,ELI(N#4MAO
M5_&5T2J*568 7.T[((LFS  W/MSQ<N3'<Y->/MA @V%HB219Q0Q(@7<(EG"8
M6@% +@38MU9CD;!1^!LUK;Q69'C-,%J4LIS0]ZW1CDIN$$JN)RSWKI1<0Y--
M)U]:E768560QP:[5TA=*?[*]YO#3FO.#_%FFT;=LO]QLT*[=9S=-4[?)C^GR
MUE[AEE!;;AG-I>>X&2 .A[0MW>,J+>,0E6X<?=),3"&JF)NORV/Q8[2=^1,V
MHC)KNO#O,AV6 <^*BDT:BPF8:<E% PE#:M>FWS$UHSX8A#[H"7@>J#ZX"W4@
M%@J)/8A(A(!-0B4@Z*# KN0HU8[5XUYD]WO7SO7)./#@%G'*S2O%=: /:$;Y
M"N*>X*)6/E+MD8T[S1H0\#Y^AW+AVW'NFAO=I42OSL4R"M,_8!+A-O=Q ^/M
M\C3#1G(Z6"8H7YX8!HC@6"MXS8TOTT$>IVUBF9=QP>T8_*TOC:N, S/2 %)D
M!NA78W-N'JU6X$?!2L<;83N5W+S)L(&YDU'8BI[CX/DPS@@"71$XPV]12%R#
MA=4C.)"(J0=WT=[)3O$,VZ:JG$.0L595ZJY:.#/R%?4VM(/'/P]'[,=@E)ON
MI]Q<A8*<J"#)E!O&" +C-^IF+E^1J5#[3E@CLV$)/&T57^!APQV?_RWF!>U>
MG(Q//K@9E'=&I'>Z2*60W10R7:59:*)8SZ/T+7A-3#DHH2O\F?GZ[=^=#ZD6
M"7^,X0L<WR+>5-X$OA6:ZI&-F:#B4KGUU=:42D=?)G.,B)F6V^FP\HI:[^A=
M]XI--XSSX!+],?LVTXLHQS!6*%OX;HOZO@,FG8=CTMDDG4^^B:3SF*V\PVQE
M/R35'Q1A5O7\VK56<7?&HFX:CR#H09@/-TBD.5' &B,@F:3JT+\^!2)GH,7(
M864F&^TS]MVG$TXT49,0P;$UG:/1]AR,\-P@F[!3>&8B/-O#O]Z.Z*\1I^FD
M(4^I"?U$XL]U"Q1[O95)[(#DT4^O.VC-'P_>:/NJ1;'?4=:/%NXCM0(',V@@
M*S8LF(WLJ*Q")^64O\?2WEJ?N]SH>]P1]$]]2.R@2 M@R.>Y[?I,TBZRF>"S
M*D<E..$*"\5\L@;=:W=QF>B$*HKQ;N3022MB<E@Q@\_QM<1$-*0KC?,[;E7,
M6H+<7RY+YD+^VC5V$C",PTT(JNG 1PK0&(\I3H75+JB-U0SOT+EE:%07#-#Y
MY5C.?!]:HQ]AP&]I&,WAJ0:OYR[XJ$CJ8_AC&<7Z.C72B&92<AC#K%%(L9"N
MCK:L"7A[FZU%19:8KXJRH%SE!2KVW!>F8NQIL4B(%[^YUW);G@2'.!9D.B 5
MJ@R:JRCF@@<;*>8G"U$ZU0=QN(D?AA[23/KR<>>@4 >QRLS#(]O9J*GS;+DW
M>DGAG\@?9M3>91J1R;)(N49JDU*(6<GK73L3MF1#"-M%>O$32]O>2/3/RJ)*
MK%W":H<X=-*P%9>="=QE&CZ[0M\PU-AEA()8]#Q*<^3V&LZOV:\S)"*B,P#1
M#1&W5:6:+45XA(*IL?CG%*7FGV,@+TC7PMV2JRBL'1Z6;\M06=-4KYR]2_U4
M<7WAY=RN!O#9)Z2YD#>N:"NBR[')ZKWHY7X\$Q]J)W/2ZI%ARXT6*-VCIKX.
M6=W!.V&R1IAU;,5Z<.-:Y35+RT1<--CI,^K=9K2/TT*@I?ISU#!4FD:J1/HL
M5S!OBT[J!%\;N[)'(]%QP][AAGW<:\-RGU]8^?\W__\XA3R:4KN)8:[WQ<C_
M<CR;-1@^F%#O")6</__G"Q>OP^Y6!:0VF\D%[U:X 3R?F?Z:<UGI>@E_Q*LT
M3A=1X,TQF&^.>,QN8(%WHLN,OX<_^ IA?&J/[FT91*&*5C<9(3F#74/T]A_A
M2)9SGZKDI%_]VQL0B3B&'8!T N^IPU$Q%+Z<P2B0<PR(1(ME0>Z3.V73B9DS
M"\^-<FUV5\4L:EV#JG*[LMG-T4]@J09%*)96<,FY1V$2MKK]>@4Y[W_KC-&#
MQMUWG[OOM-_NNP 7+I^SZN;.\ /9>M^O"7;:L_3TKT*] E;Y,II%(R%?>PS_
MFU"C#\N-0V4'=;_E%,T(\]<99:\(DVS\%$X78>5HH1-;3+JM@M0'*R1J>3;"
M&I5RKATC2P27#@6#*#>;I]C("ZRDL0QUV-GS' Y? H^)YG0*#9'*1>IJ[-JB
MP\VJU4 MC!5LK7+WHA%E/@A9Z)D,?Y4$);D^W^9BW]LX>D$$'XT000,1//V.
M(8*C4KOE4KI&]259+"LI6U49)7U60JF!?25T8 VBR[1@S<>6D;BLJBBX9%9N
MR"IP.A$="-</7 U^)^+1L[*JKWB0B5NW<#--*= 19G7_3F9?[D5P+-')I$3P
M0)9M,/XE9T$X.R_N %?"=B;8UF66EUQ\YOB?1Z>[G$;K9> V$L-2.@>Y] K%
M$KD^JCI$CNN'MG,=>+SG9IN.:;7[V&[]4(TF'"?-G:(L-&G4<>O5Q_"Q13T"
M.P]W$V6M<<)MY;V[JQH\2Q_!E<>]Y%SB,BU1L-MN0<>WPZ//69\-,?%@^ANK
M<*EAUJ5&A)%4QS:>^CM^6'L.A>['N,^PXS[$@C!+$^7-(ZP;I*6M:.6&[LM_
M)XO9,W 3&7J8VC;F%-J2^ *X.']NN9%AWZ=E)A01R'>^M6&+]FB'@ST\G2RI
M\CS6"Z*H,$S%7,U-5K*,(M;T8\O.S\_5HU -0JAZ.LX@5%&6Z<LT(#BGT^+1
M-=5$/,:E'<32]G1ZA86/^H,8@+/ R/'HI\((OL0@>$T86!HIMBT-1B#7KK89
M] YX'+%'JAC9*##WST8(,UY5,C56TPU%KGHR.0@0+"=!L#R,3%F$\H&<'1$?
M+P=ULH5U%DEG/H,#)UX2ZBFF23(K_T]/)R0?=TO<^#7Z$5+15(/;2V&2:6'2
MM77KG=OJ94:[8+*GH_=]']YWO^J@=RG1(L&BT689?>[&&-[,D3N@O1OJ+B_;
MOI8/^2K*E]HYK*BJ9U5B0M2A35H@\Z5!622T#KY#+A-J4)*Q/4RE$W9% 4EG
M*0>]+"LDZT=3.</GJ]\B6C;./:]]S2D7(%S[*&[<XX/=^5O""'BJ5QR;"!^0
M<F8Q$2I>30+ 2V3#M17-6#H?Y;DM8LA D:,!RSCA/F7AF4)'OAGA^A,Y9*J'
M)ZE'<)DY=88E"U8 N-1UO%[V)0/CAN.-6>3E)5,%-&JAQ\#&L ,;CH,BU?+5
MX6?IW41LM1,"VRZ1IND\?N>E:]C3<W2&60/@&8MR$^7FJ20O6#9G6N1M;TC?
M(%ZWY')FNS1%L;%7S^T(II/WDM.H-NIH/@]&=/N246"/:N=T0+$31O8N$]K5
MJ6,2\O[MLG[5@;^O[>IM.6L'L9"#L=-^1^A/33D+UD*T,\8DQ6(+P:)KJDRT
MS]1F/+2'?6CGV&M6-6QF<RIWN:P.$4YU"GI\"(IM;D(+?.B#\0B6J[4>FW(R
MQB\'(2X]#\K;%1?D1& U_,V(R["AKH]'J*N!NIZ-4-=1+=Y6QN[&:O% N? 1
M;$72$3GJU)W&X?1:P2!R6N8-? G^N(XP:= C-'T;*M+<'JD98;9#$<V>&4>D
M ,CTFKFLNT(;.T_H-),?&P+]1!M4MNE5ALCM:$[=>&J$<."6"2$<["+J!BUR
MA32P_K51GXH)%-\ [K+$ONUL8.JP;C!X'?;"="+O9YI'FUM$>5Z2P^)LN]&)
MOW\GOA]CR LLG>2SFCSY5N1]5$WWKYIZ^IYOYM=O8QM-R.W>][>>JA0 IK.P
M.@0)2+U5V=SIQA\%YI:]SQL*#/%Z6J&!HZQ^H,RT\RV!:.A(L >'W('/B^[?
MF^^V"B0VF&B :X0+M2:DQBSKLL@LF.?NP\VCP-ZR7\"I[LK.0)FZ3F8,%*?;
M.*I4'%P3917@:[L C>F*@5DZ3WI:.A:!A0LHZFT@RS>8),4%.;/<ML?L!;="
MJDG389V+%37M2>J<&;Q_QIS%L.W&H+XS4.TY_$,.N$"*WY#,=1TK4+](09YX
M!T^:< !N=N7B ?3G=91M[-G;]HRW(8":;=;9LB@,SZ\EZ2U@\KG_+(U,N+%J
M%,>*6V]C\U\D(";B2T14^'B_)*VZ8;AMH^9S!\8@[%M##YI_)^+=T\K=81CX
MB-\V=&F[8BAD)H0ZCBXKU%>%<JLJ[JV US!DS&&=RQA2:F+&,>^ZJ?V245EW
M)ULGQX^/SFX@7-^:;/'>VBE:)%E1/\D*RW@#FDT')8;0\B5A!<UBPO*N\CN'
M+HTKVG-%>RZI\M;I%1]\"H:6)9IBM73:X(J:7AN,QK2$\](45$Z=2C.@PYJD
MU,R&\A<ZX18;]:OPB\\Z"Y"JBA!Z3-"!G1.O$KCS,EIWL'I420DPOW*D/ZR0
MN9<IH0;X1N-Q-8CCJJ>/VQ @/'C6BALV%&FAXD:=4U@VT=2[\F2M,X]%L?O0
MFVTXKQ6ZY=8@?/,R">U39BKY9'HE'^2'E*O#[ 5U"2Z\1ELJXR'4CKP1WSD8
M&>U;=N=:36WWP3B0_>OMM@KA=$([P/4YHA5UB]9IF<>;478&(SM]FR0GTM^%
MO#^'T=,MS_J(Q%0E2-&C,<!V_P&VI[T6]C7XU-37(C4J@37!N#N'L#MOED/<
MHJ=_1-KQGBXSAEC0("#( [;[QC^,;&RD!5%4Y#]RX-UE;&AUL#KU:^3GE 8J
MBV5*I.K*6-]L1J,S)AVBQ%U?UKH164,FJ9X^G<ST4L5SKIMR'R. [)I9[ZU2
M<0N*# \G:W[]UY,VG5"J06'C]Y:+,*L%IL35D,?4#UONZH N ;\0O<2Z:$2Q
M7-O,?2^*\N&,P,QBLU!DSX7OLX5N1SX.KI:ITQO#MJDA#)6]'GM&.>W=&+="
M#\L/C[QS&RRL[HM8^)G6"=8PNJ]\S>M2/T"T-#-TR*U/Q9=C\2'Z=@*6H5Y4
M3D-";,NC-7I/>?V-3.<R(:K&F6.!&WKN<-C8V2<C=M9@9Q^.V-GQ!+]%4(=J
M'<1Y=0RSY]Y!8-AIF%>G,$^Z',732;O^&H]+[DJ&;0;G"KPT0>Z"CC>M8"W9
M3D6],\?S]>#134I**>9FGS*="$#XH.3. G3BI\D#IH.@U\$#99WIRXB\1CI;
ML! 6]#V'*CCM8[-).1Q6^5S5>CJVWE@::LLH6O5<M4,$)#@J8GY6%>NSK+MB
M!/'Y1&O%(4"*^L5\<E(?Q40)C2M3V0L181"M^1I340Z'V9QXL.9UR\EP8;G,
MDWS%.=XF=FB"D3B?S8<P @.B2#&#MEZG2&EB6XA6[UZ'8Z<9<PG#E(=D>J49
MFG\X/)R&PVIRQGS'$*+C_51+0XZ15MHT=:]D!#G8[IIW;US7V\UZD&OQ[S+*
MA T<JRY":2%'JXEJJEIB9 _(0O9*,!H-(D%.%YC*:5:N[KJF85S]OJN_W[XV
M/B^9#.3]2,L,3(#Q.6,/9SE8QBC=_4?IGO5::^E/-9#U&A3NS04+F6:]G[1>
MURPHW@4$<2Z8)I!'8AI_(QK5 $9!BW(:%W_(-BI:060DA]XN6)T2]4N<@O 9
MV-N95_&TB%%HV@)B.(5OO[T[[]C>[PMLPK.>[?VT  D0'HG8@.$TB?M^%>A9
MSP9_%X-;L\$HT3;[^W1R=D01 ]?A] *5H$]LI!]AEHG41'9D!BLT\78*1]IY
M(X/C%]\R-VM74G3H/8PDF/KNI<XT08?'C=6T3FK[1S(T-MQ5[2/RQCVMLC@"
M]XPB9W4SPY2TM/J/')+!$B4E=2D&&T=8&A4&E9SE:^"T96FG$U2+-9PV/D$G
MTOV$:K3(H&H_I0*+&SFA\[&$ZV+WW4!0.EI'+*)+:P?9L.1[1=TY*/@F$4%X
MCSSZC%DG4"N)I11U)9$PZM3#I16MK(TLS4S4@T'GG>,?]=%]Z*.>_5SJZD?:
MQXY*9Z?26:D-)86;VD9V@02$#66'TW[,R=7:2@RK#NS=,*&?8G0AH)8,>/IC
M-:K9J4F5"BC7:%<(02IS=#C)8,1@(VJ6]$6:U!X\[LG[V)/]6)[=/3FGVF#*
M+(R;LM';K'4"@AU0/Y+?I<F#EYUYF783);O[&A9Z990=.#59SA*UZ74L,<"U
MS,P]!I=FIBME7@:</S+V2_>O31]?9$-A;%%%GN*A$!XL#[UH/I8B#AM^MF.!
MN3E/3K0YTH\!$1!P"(!L(" '84(HNO0A0XZWM0**\NFD$O:#JZ4FF:6T<G53
M>R>U0G0[MQ?+]+I$>O0TVW1="O^&C7-H@?8$D;?WR9"N9TT9YG3.^>>-5"/F
M''G'3^H_,GQ"5S#4C7=PVN)>ACL) HJ9@_@ M?F<JA66EZ?2_5,.Z[JFJ&6O
MAUXS,FQLT],1VV2P38]&;--X/-QF*:])Q%C;I1.YA)K?D'=XYTD0Q3&B?RNE
M#XJPHM/O/G(XZ9*TV\8*:H=(E(0'4,IY*82@7-00QCLR%12E!%"&KEB_$X&[
M03&>67.5$ZALBWD2:A9(B3HY6'2\QULPEI-<._)7DUE!PUM[]<G1R='I*"F#
MD)2>)7$[+%<L_*_CZA!2C^6057,$-#YGV.@* XC8N:XB'R6CM5"?R$1#C93G
M>BSJ'8AT]"QZVR$=*_6).S3!NL*/N/NH5&;,=*+G$<70 K#E(T)?+1C! 4*2
M&G O:)LUAN=07$(]*]R+N% $3RCPH#35"Z>,^[5^5-5-%9=U!@<=>1=R@FT9
M-]\OQP>S0Y,9WX9(,-@E049RA5Z(N4K.21PH-2$*<11EAG48&-P;I7H04CWO
M29:0>&\2\$0NP:3?>*\N*=P;!&76 BYOEZ-QQ0>QXHO>>BQC\E#OQ5(E"XIC
MO$ 3-XUWZXN1Z'HH2[V\\5*O=+:@QMF4*L/(0\W%V7) D$E+SA(%UZ1(DV)L
MU$L;DS/IG DH"'X:D2MWB?HD] *MI%9%?X[R8B@ T\$D BYVN*V<6H.#MEC2
M(E ;QSJ)_O8D@2UW046>4;!&$(SR!7*^<6E*14Z. 78A)U\>&D8'9'[=^A2W
M6JB=6*"NAZHPM.@W:#Q'HL4D)%QQ.B;][B/IUZ^%V!=D&_\:]_@?'/HW!7+3
M22OP[U1V=VTC?Y=^9BV![@=Z'ZG;T'3'OIUMJG*[+92-':TWT-8G9(T'+["(
M;9OLPNE(FY9QB+# =:;7Y#,PVF=,V0T\99=6! )MPI_MDC0:A$-9Z+[!=]-M
M]EH=T1:#;2G_4=^[8S@ 92\01\8Q,&N%@VS*-"A84Z7'A<Z-OD=\L:M\1P/H
M/@R@?NU7*A[D<2_\%[9/C5+0-7UV*"E;@0X#V.G&"C@$390H7TH'%'ODI9G3
M@[O:@-N*&1ST=6O(XT:]CXW:KWO RRA?4XTS!]NST5MIC>%-\ZBOTV'83(7U
M^IL=9MH[Q@'P/?(D)[)C2X>I9%^9Z=UL.J2AB *')M79INLLQ42<);3HOO.U
MR@2C&4XARZZ -U):$30+L0-;Q\5\7QK\IEF,6H<&2+48H5YKFG8/2;F$&8OY
M5['*H^&4$0RICJT\0%H37!U%:2?]>0T;RK9UXP]5-HN*#%%NA\P!PO>IVCW0
M#(>$Q3935T-X$^=98GE@T#^UJ>^KFZKV[1/_/UF.+Y6;F=]64^NWJ4O>PS1'
MH9-M [U.0'8M? =<T6'(#3#.;>?[W,XW*?I7X-)RQ6[H_:&01.5 4FP2]#0K
M[#P OL%"8M.L=UXF@>DN@W8?QD>Q]4"DXD.#?F_1J.V:F8YELQ %?J)"PIG,
MZ6[0HE.C-CA( H<?!"ELRPQ66^417E1<(8>.@M5DUCL\!87-M?JP8G3#S^4]
M^ [TCH2?I.?Z<-"J0E_229M[0:QR4$Y+-G*G$R(BOL2W@8%DR(2-_7BX\ >O
MIWV<N5/#%TM^W7D]I)(EIFX8)4R5EF@E10T]%7*3'Q4S^T%8!K#<?"L$C:JB
M0%1F:-#).-<B+F;V-MYEE!7X:*QI-!%)<R%2$F513K_)I'3(VA(PQ6C>RY=2
MV40<AP0]7:D_4\R4$@H UI'^L"T[B!M:FC$R%7V@UA%^6*?]._+.$2>=YH6U
M0YJ;>X:\Y[LUXI'WVI1E<@3?"%=-/%F\Y$;RE-O3I ;CNO/8$7^J%:5P="UC
MRV_BVSH_EEHQ?M,\=57V .VY^QM(+]SLLQ$W:W"SC[]CW.SHN?3R7/K1,E\X
MS/VU"-'HO73$&XJKU#LXK;*,TXFQ2:\Y%SB08,RYOK$$KRN4X!JQED<!0TIX
MA>,2/?&-60C&3X8 Y8X AXM"K5B0([!KLQ*M<:)HGK<[?M5#&;;="1_V[1(O
MM5!X3\1Y&7CKO*R*,[<[.H;]O^8]\-"1D9<(Q9=RR!HD+EJ7TPFI8+Z[L3(K
M=P#-1>ED:AB$<2PKO9J1>U)G0NXF4ZY&.<"3_#O0;_T(K:SSB&XQ&<RTWHS"
M'[5<?0S6:#=LJH35[$1@,/\"PW6(YB"7>H9KFP6ZX96V*D/-]=0[L+V*J$S.
MT6'2DJ;BAT7O2[P*ZU3C5V&9V19^!L]:D%?@<F,YO%H1OT$N+#5P:X?S^]!W
MG-$ZD"9,Q8<D;O H88>3VD0Q 2(36L"_TS6VY=$-PC"&TV3P&%2] 2A2YB3'
MV\R,],+TPJE 6">NK+?Q E68:G>*&;=7ZDKEPBDVZJG[T%,GQ[T4U6\:#JDD
M"G+WO!WML Y<6XWG"=QYVPQ&# ,,A&TH)H+;TLRD$X393JVWG2=J),C[ IOE
M83^"O)=:A7$:?!K(YOA^E=O#GJ1X;^9M(QY#D*4TYX6MFF48[T?*&*P*H>V-
M 6'GX([Y[$-@J=GQ9[X!B.6V7,423=BSLV[-^Q@_9"YWIBW.J]2#"5O#Y2OP
MM2XU-P-):% L<U48-,0?4:AWJ2XM(#9T:QOL6/@5CKP_X&84Q'9N&.7;;M6V
M.3#^Z3=J_C5RP8-7^O006_'9UR4<KD27%3BJB/)-;+B88[(\ K\+ =SVX>A6
M8MZDZRB).%YO4.#V?0Y<*@_YK(L/A%IEX@YR'&-9ZO22O&%CU+3DQCR+3)I1
M!]RS#NC'\G?17$A3N"@>O BUZM'ZH>FE5# R%@M$EAO*0&E8Y,#="23E2AL+
M&N:2MN\1\_>+I8JR%0%B>7/NY*^:3NB:TC1NK3I(8(Z6@B;D,5 ?I;FBA#32
M?%#1%#^?@06CF-^_F/<CCY.CSLK-4N72Y(-:BN1<OF(T.'QV<')]U0+C^E1<
MET+L?\64-=9^A<W83/%_,+]]3_O*U<%RN'70)AZT>JP];* )7T=97FPC:)I.
MZGDZ<7*I0W*NP;<NZ21!'D;OI-;0\6%K^"E\#-NT"S;.V]6EF6O,:P=V@(Y&
MI&&PJ='&!%50]UFY<1GD6B>B#2<VA@QSEH(&V#HWXH7,J20V7[+1PR'0M7F"
M8>MA>X*&69^(UD/M]>^SQCP-7GD,.^UX>CRF'4W:\<F8=AR/R=W'9$\^QPZ-
MUN%95>UC[K01U%@,<LM5/[9B3, ]+6NAEMG$93^8,9TKZ,(5@Z,.JZ[@S?/4
MG+SV+)6 >.,0'+M_#T9N>A81(;8TAC,,,Q@8"+E6AEQ85EM.MDD6I;4Z[VEM
MNIV"-7B+ZJN6JG[G3+\2XC]V.EKUMI$=5K:_3;"HQS15YXC[9$6*9#:OE6*Y
M7+-P0/9TC$YW.T95;5"':S0*Z/T+:+\2KX]U^6NM:M47P?;12]Q63Z[4.4XC
M!6:)]#@<+:=!G( ]+2?1"('*&VN+0 (5)9(!<=0)W-G?<D ZD&UINVYL+I_C
M[UNT6_MW51';5F-,CLS1Z!J,R/4TNO80N=D-1 Y%AYH1,W*GE[A9,>UEI0WD
ML!L,2*)=*B>@J5J#+&=!GX[(H/NP$/K5EKZ98^G1)7P<=I@'D0%W25=MYX,H
MH5JHH(@W!I>GPT-;C]?:AQW9A$>2(KCQ\>+=^'1Q3>U:C4[3)=M2.KU3N >A
M'[YG4>]7C/"BA1[-E93@N55PA8;+E"W6K*>IJAK4PN;0?(%*XGUBA;#6Z](K
M1]ZY@"<J1*M?P[-FW8P!H8ZC2V'#4R4GDBFD21^S/^B TEL%:50:2F!/=#&Y
MJ?8APBM*V,6"U@\=4&WF(-P(>8)O9DMCMPVV8T\QAM^ZL=7XO![#2[C(& $V
M455#RS"82VT*#E&DB'=-5WS'7I@&5&G V3GL,@WSG"XT.]66)9 !M?CTLEAR
M:2-K*\[>,Q"Y<U8(4D/I5S-]OJU'J# F6]Y7TOAK3F=>43FA>8K!&:GDDRFQ
MOF[>F26\V)G80_^..XKH?Y=5SM>&H*83BD%Y*ZP@6<?U^=:7B&M,2JQC<,M.
M;=$N%_Y>)\2,G:1)Y542=#,NM,PB.!#U2ZJ%%"SXEBE%P;%(B$U5I9DR#$F#
MZ1G8=H3M_2\S;-[5A(!')7__2KY?1<:[M"7RL%_;E@U!"/B #S-UA=N7XFWV
MQ#?-Y*1!7P<4A_!W%86<1?@00 ?5 M9Y8U8R5U'8$6GQ9A$7C51=@DR5>@WP
M8QSDFJ!V2:G9\[!VB3A8.\ZR4:;O7Z9[HO=;N'3O-F'I?25A!*E_ 9EXU ^D
M_D&O85%APA03=S#[1Y9A#X<Q9-$<PZLM6$JDPY%YY"F\XBG,ZSAEM-1')M"!
M1[8+P]?"M;]LT9/K8$UZY/.FNMTH(0H5#BHP%\[6=GW"E*:D%/JEM4/IY,<2
M@9KMC^7![BG/D15\5ONTS_&XCXJNF(-M(?4U!+P'W0_O]&0$V!F W=/O&& W
M:MP[Z(<'\T6$#J).)0Z%X.<J1BL*EG0;>"'44<AO*E;/T:L14V-BM*F,P;F1
M[KJFX2GW [#FL"EF5C@/L72UDJ9Y4K?--[)=>F,5K8C1#NW@+)0F>B9HTUV>
ME&:<Y# \5J/%/!B+^7$_B_E%FLRY( R^P?4FSKPD+4$N2? &8C1_F]JGWT+V
MJ_=LK.3 C:.O>MENW4R_<",/Q"G)/$08M7#7U7N3T*%!UX51'L1$E&J[95>-
MI7T/WF:FI"4=$94B22%=M=)*?&/S.\XI\+5HC_-?E+;$ED#OZ2AHMHSGQZ/M
M3M_7JH2$BY&?U_GS#\@G>DFIF/;/S;BD-9VE973KLRA:8YMWWFG8;I3W6S:2
M7C)/#&5MP)UK+R>?0[SF+H=EUFKG6_O57.AH.-6!'"VJR%,L_O:E[$R$3F22
M@H1WBM4[.7Y\='8#V?G61(>WSD[)(<&)^@G.)ZW70BRP12L&SA=WVLAP7-F>
M*]MS:=&W,4?:[B6N'2Y"YVQ#DHF+3HE 'S0R5C;9WCR_^.S;QG>>>VB('02<
M=Z=_AX=W'H4:9:ROC-U R,KKY,N<(NLR0R)Z5[::GKMXV:T(*;K%HWDR./.D
M9XOY:\V3;FN"T3G]-1BI(A0?3$>G&\T('15>1CGS]<--4D9?-$@R_YJEY;K#
MHH[6$3RM:8ES^7UAJ6D8L&B91Z<30P(J I^/YO5 Y;=GX_N+;:9NG;^5 H=6
M:IC/*=2>ND+@& 440T;BH3?*H# I2&@Z;Q;:5LOBS&O&6(4>:YKZ.=)-RFUE
M+%?4#(!#D"8S7PFCU_&"AADRTRLEF#P81(2\+T:?5Z'2>J;_L<%RV>>/XCX(
M<=?]Q=T5O*X2"K'?9J00Q7RK^DTY.!&0DVUJ6S@_1W]Q"!9?S_QW[D*2NPYR
MU T.F<UU<28?-2)ARBRF&"0OF$["E/1.S5:$4WJQ;*J=2O%56J>FJ45;664T
M>K%#D+>> A? PL\0?)U>)=L66"3'82;+0;_D<\GY;?-/#5,APJJGDT\)/D%N
MU7P">[[4AT=@R%6PV/20Z;A]QZU&X1N$\/64OKR<Y01?D/(C>*M872'R9^-H
MK#0'&S]W1*TI/L2%5LL#WW5GX%$2>DK"9>]S3S#^H2F&<14 "(4Y9I#[O&!;
M?;76Y"3^">YO'D:F2QM<M$!RT 0/+17[M@L:-;W*]**,L2O=QH&4&8-;L%U_
MEN'"G+8,&S"C6PF&O(KG5<.PMQNM\4%8X_-^HH?L'TBIL<XTK+NPVU;KFR%S
M;LXBL-(AN9;<+L")HN YQS$6_ RO40$>>+$.%YK+FKF?)/FQH5JI!=Z'VM4S
M\2-5](18S%-H?M*FAQ]HP#EV:!B@2?Z41H"^X7H(W!@@%_7SRZ%0%W2B9QJ\
MYCD1Y[K-8,P0P#;4\#?Z*/A)4&#141W*0U4^%9Z'FT'B!_ ]<JC@4.!'YN6E
M:&KFMI0Q<1V-/DQ@-QN](2^#XY!7TS#X$HB!<Q>>CM!* ZU\]AU#*T=T4R]T
M4S\FZ_,OA4D;[8%;QC9]E-X^QOOHI@P .2""$SCBQ%(M!?CC+'RCCY"6WCQT
M"&.G-GF2(;1O!5QLF3K%N3'?R[U99V2Q8MMD#5?,S0E<"\=P!L8<GPM*P(C5
MC/77]#9DR$BK8/XQL?3+3Z_$,&JGILE"N%0-UF-C^AR(?60NDAK-O)I7)Y*
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MS$VK_6H=>^RN%P=:&JOBVR6AS '/ I,ZVALY9'BYNP3XIB,@[Z: O(<C(,\
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M+9K1-$*@W 1V_,;C_NSXT O51JHNF 0^T-':5N75%%!!#.5&^;1//0-,@,-
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M^M,Q_Z2:R#*Z,!U-J,O)=*: 4V<[9;F:5Y?HH/!)FV=9B5A\PSP+P0$@R),
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M2WY'_H%R'FFCP7C;B4$P0=]3X#HH"^O<N!6\90K>;C/!.XW('S,0Q)<:!B%
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M5Z"#E*"PK3OFRT#*P=I]/_/XTSA+HFM,H+3[?AG[_DVS?3_#PJ+_P8+'#$F
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M:NK-\XOUTI!W[EH3]RZR>X:],1+W77MX9N-N;MPO\=)=PLYMHU-M=*J-3OV
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MA<H>=_;WBIR?*Q-FOIJBF=W<J/&[XP3+%C)"W+'V.Y<YS#K0BEL812;%-I.
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MX"O $/LAU=.,)R6E%K@B'$+V5)",\[)]K)>H-" 4>]/IWK&(Y'QLJG+[)ND
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M+GAS9%!+ 0(4 Q0    ( $Z(2%-5D#!\_0H  ("&   5              "
M 6(#  !A8G9C+3(P,C$Q,# X7VQA8BYX;6Q02P$"% ,4    " !.B$A3=%/N
MN%8'  #95P  %0              @ &2#@  86)V8RTR,#(Q,3 P.%]P<F4N
M>&UL4$L! A0#%     @ 3HA(4UHEE;4Q'   9(<  !L              ( !
M&Q8  &5A,30X-C$V+3AK7V%B=F-B:6]P:&%R+FAT;5!+ 0(4 Q0    ( $Z(
M2%.)$[^"4IH  #=7!0 @              "  84R  !E83$T.#8Q-F5X,3 M
I,5]A8G9C8FEO<&AA<FUA+FAT;5!+!08     !0 % %P!   5S0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
